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Colophon 
This report is published under the acronym MARAN-2009 by the Central Veterinary Institute of Wageningen 
University and Research Centre in collaboration with the Agricultural Economics Research Institute of Wageningen 
UR, the Food and Consumer Product Safety Authority, and the National Institute for Public Health and the 
Environment. The information presented in MARAN-2009 is based on a collation of data from ongoing surveillance 
systems on the use of antimicrobial agents in animal husbandry and the development of antimicrobial resistance in 
bacteria of animal origin and of relevance to public health.  
MARAN-2009 can be ordered from the secretariat of CVI-Lelystad, p/a Houtribweg 39, 8221 RA Lelystad, The 
Netherlands. MARAN-2009 is available on the website of CVI-Lelystad at www.cvi.wur.nl, or www.maran.wur.nl. 
Annexes to Part I Usage of antibiotics in animal husbandry in the Netherlands are also available on the website 
www.maran.wur.nl. 
The citation is: MARAN-2009 - Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the 
Netherlands in 2009. 
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Summary, Conclusions and Recommendations 
 
Usage of antibiotics 
The extent to which antibiotics are used for veterinary 
purposes in food producing animals poses risks to 
public and animal health. It is an important 
determinant for the development of antibiotic 
resistance within the treated animal populations. 
The main objective of this study is to obtain detailed 
insight into the exposure of farm animals to antibiotics 
in the Netherlands, by monitoring both at the national 
level and more specifically per animal species. This 
report provides an analysis of total sales figures and 
information about the trend in use per animal species. 
The results can be used by the Ministry of Economic 
Affairs, Agriculture and Innovation, that 
commissioned the study, to measure the effect of 
policy. Moreover, the usage data can play an 
important role in explaining trends in resistance that 
have become apparent. In addition, these data can be 
used to provide information to the European 
Commission. 
 
Trends in total sales of antibiotics in the Netherlands 
Therapeutic antibiotic usage on prescription expressed 
in terms of grams per kg live weight has doubled in 
2007 compared to 1999, but has decreased in 2008 
and again slightly decreased in 2009. During this same 
period, the antimicrobial growth promoters have been 
banned, first partly from 1999 and as from 2006 
entirely. Recent figures indicate that the sales 
decreased again with 12% in 2010. 
 
Tendencies in exposure to antibiotics in the 
Netherlands 
The figures on exposure to antibiotics in the 
Netherlands expressed in number of daily dosages per 
animal per year in the sample surveys reveal the 
following tendencies for the years 2005-2009, 
indicating a decrease in antibiotic use in most animal 
production sectors in 2009: 
 sow/piglet farms: annual variation, slight 
decrease in 2008, increase in 2009; 
 fattening pig farms: increased usage from 2005 to 
2008, followed by a substantial decrease in 2009; 
 broiler farms: increased usage from 2005 to 2008, 
usage remained stable in 2009; 
 veal calf farms: decreased usage from 2007 to 
2009; 
 dairy farms: increased usage from 2005 to 2008, 
decrease in 2009. 
The usage in fattening pigs in 2008 was statistically 
significantly higher than the use in 2005. Also the 
usage in broilers in 2008 was statistically significantly 
higher than the use in 2005. However, the findings do 
not permit a distinct conclusion that the use in a 
particular sector in the Netherlands has increased or 
decreased, because the observed differences in 2009 
were not statistically significant compared to 2008. 
 
Trends in resistance 
Salmonella 
In 2009, Salmonella Enteritidis and S. Typhimurium 
were again the most frequently encountered serovars 
in human samples, represented by 33.0% and 32.6% 
of all Salmonella sent to RIVM Bilthoven for sero-, 
and phage typing. S. Typhimurium was also frequently 
isolated in pigs (15.4%) and cattle (17.4%), however 
was not detected in poultry in 2009. Importantly, the 
fraction of the multiresistant DT104 has decreased 
compared to previous years, both in humans and in 
animals. Instead, S. enterica subspecies enterica 
1,4,5,12:i:-, as elsewhere in the EU, is strongly 
emerging, representing 7.0% of all human Salmonella 
isolates, and 11.9% of the porcine isolates. This phage 
type also shows high levels of resistance, in particular 
for ampicillin, tetracycline, streptomycin and 
sulfamethoxazole.  
Among animals, S. Dublin was again by far the most 
prevalent serovar in cattle (59.8%) and S. Java in 
poultry (41.5%), especially in broiler chickens. 
Noteworthy, S. Enteritidis was isolated more often in 
broiler chickens as well as in poultry meat compared 
to previous years and also S. Gallinarum was 
commonly encountered in poultry, the result of several 
outbreaks in poultry in the Netherlands in 2009. 
 
Resistance against the for human medicine critically 
important fluoroquinolones, the first choice 
antimicrobial for treatment of salmonellosis in 
humans, was common although differences existed 
according to serovar or phage type and host species. 
Overall, 12.3% of human and animal Salmonella 
isolates were reduced susceptible to ciprofloxacin,. 
Generally, ciprofloxacin resistance occurred more 
frequently in S. Enteritidis than in S. Typhimurium, 
while in S. Enteritidis of human origin resistance 
levels were higher compared to levels in Dutch 
poultry. The latter finding suggests an additional 
source of infection for humans (travel, egg imports). 
Also resistance against third-generation 
cephalosporins, critically important antimicrobial for 
treatment of severe salmonellosis in humans and first 
choice drug for infected children, was present in 
Salmonella isolates although still at low levels. In 
2009, 33 suspected ESBL producing Salmonella 
isolates were found, of which 22 were isolated from 
animals and meat, 5 from human infections, 1 from 
spices and 5 were of unspecified origin. Of all ESBL 
producing isolates, 22 (67%) belonged to S. Java, 
which all originated from poultry. 
 
Campylobacter 
Among C. jejuni in animal species, highest levels of 
resistance were detected against tetracycline (45.4%), 
ampicillin (40.2%) and the quinolones (37.1% and 
38.1% for ciprofloxacin and nalidixic acid, 
respectively). Resistance against tetracyclines varied 
among different animal species, with very high levels 
Maran 2009 
 
 
 6 
in veal calves (70% for C. jejuni and 96.8% for C. 
coli). Among C. jejuni from human origin, 26.5% was 
resistant against tetracycline. However, 53.2% of the 
human isolates were resistant against ciprofloxacin, a 
further increase compared to previous years. In 
contrast, ciprofloxacin resistance in broilers decreased 
from 63.3% in 2008 to 42.6% in 2009. Among pigs, 
the low level of resistance against the quinolones 
(5.1%) in C. coli is consistent with previous years and 
unlike the high levels of  resistance observed in C. coli 
from poultry and cattle (up to 74.2% in veal calves). 
It should be noted that mostly disk diffusion is applied 
at the regional Public Health Laboratories, which may 
result in discrepancies in resistances levels between 
human versus animal isolates, as disk diffusion is not 
standardized and no accepted interpretive criteria are 
defined. 
Resistance against macrolide antibiotics 
(erythromycin, clarithromycin and tulathromycin) was 
more commonly observed in C. coli (17.7%) than in 
C. jejuni (2.1%). Notable is the high level of 
resistance in C. coli from veal calves, with 25.8% of 
the isolates resistant against erythromycin, 
clarithromycin and tulathromycin. Among human 
isolates, 1.3% was resistant against erythromycin. 
 
Shiga-toxin producing E. coli O157 (STEC) 
Among human isolates of Shiga-toxin producing E. 
coli O157 resistance levels have been traditionally 
low. In 2008 an increase was noted, however, levels in 
2009 had returned to conventional figures. Highest 
level of resistance among human isolates was noted 
for streptomycin and sulfamethoxazole (in 9.5% of the 
isolates). As expected, resistance in isolates from 
cattle was more commonly present. Resistance against 
streptomycin and sulfamethoxazole was seen in 32% 
and 20% of bovine isolates respectively. Notably 
resistance was further noted against tetracycline 
(17.3%). Among Shiga-toxin producing E. coli O157 
no extended spectrum beta-lactamases (ESBL) suspect 
phenotypes were present as all human and animal 
isolates were susceptible to cefotaxime and 
ceftazidime. 
 
Commensal bacteria E. coli and Enterococcus species 
The level of antimicrobial resistance in commensal 
bacteria from the intestinal tract directly reflects the 
selection pressure as a result of the use of antibiotics 
in animals, especially over time. Resistance levels in 
commensal bacteria E. coli and Enterococcus species 
from pigs, cattle, poultry and their meats are indicative 
of the occurrence of resistance determinants in the 
bacterial population in farm animals. 
 
In 2009 in E coli, the resistance levels showed a 
continuous tendency to increase for most antibiotic 
classes. Notably resistance against beta-lactam 
antibiotics is disturbing. Resistance against 3rd and 
4th generation of cephalosporins, indicative of ESBL 
producing E. coli, was detected in all animal host 
species, ranging from 1.5% in dairy cattle to 17.9% in 
broiler chickens.  
Overall, enterococci displayed high levels of 
resistance against tetracycline (92.8% for E. faecalis, 
71.1% for E. faecium) and erythromycin (69.6% for E. 
faecalis, 56.7% for E. faecium). Also resistance 
against streptomycin was common in 2009 (51.0% for 
E. faecalis, 41.9% for E. faecium). Remarkable was 
the increase in resistance against ampicillin among E. 
faecium isolates from pigs, broilers and veal calves.  
Vancomycin resistance was observed in low levels in 
E. faecium (1.0%). 
 
 
Conclusions and recommendations 
After a period of continuous increase of on 
prescription usage of antibiotics in food animals in 
The Netherlands, for the first time in 2008 the total 
sales of antibiotics per kg live weight have decreased. 
In 2009, there has been a further slight decrease, and 
recent data indicate a further decrease in 2010. Sample 
data about the use in specific animal species in the 
Netherlands indicate a decrease in antibiotic use in 
three out of five animal production sectors examined 
in 2009. 
 
Overall, in 2009 the levels of antimicrobial resistance 
in food-borne pathogens and commensal organisms in 
the gastro-intestinal tract of food-producing animals 
are stable or show a tendency to increase. ESBL-
suspected Salmonella isolates were detected in 
different sources, but predominantly from broiler 
chickens. E. coli isolates suspected to be ESBL-
producing were detected in all food-animal species, 
but again predominantly in poultry. ESBL-producing 
E. coli was detected in all levels of the poultry 
production pyramid, indicating vertical transmission.  
 
Based on the data in this report it can be 
recommended that: 
 A detailed and independent monitoring of the 
veterinary use of antibiotics remains important to 
provide an adequate insight into the true exposure 
on the level of animal species. Insight into the 
exposure is necessary to relate the usage data to 
the development of antimicrobial resistance. 
 In the next few years all EU member states have 
to develop a similar and uniform monitoring, at 
first based on national sales data. Furthermore, 
within the EU also an additional monitoring per 
animal species needs to be pursued. 
 Antimicrobial resistance monitoring remains an 
essential tool to study the emergence and trends 
in antimicrobial resistance of animal and, or 
public health concern. 
 The occurrence of Salmonella  and E. coli 
resistant against third-generation cephalosporins 
in all food-animals species involved in the 
monitoring, and the demonstrated genetic relation 
of these isolates from poultry sources with 
isolates from infected humans, warrants a 
continuous monitoring of the genetic 
characteristics of the organisms in animals and 
humans. 
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Samenvatting, Conclusies en Aanbevelingen 
 
Gebruik van antibiotica 
De mate waarin antibiotica worden gebruikt voor 
therapeutische doeleinden bij voedselproducerende 
dieren kan bijdragen aan de volksgezondheid en de 
diergezondheid risico's. Het is een belangrijke 
determinant voor de ontwikkeling van resistentie 
tegen antibiotica in de behandelde dierpopulaties.  
Het belangrijkste doel van deze studie is om 
gedetailleerd inzicht te krijgen in de blootstelling van 
landbouwhuisdieren aan antibiotica in Nederland, 
door monitoring zowel op nationaal niveau en meer 
specifiek per diersoort. Dit rapport geeft een analyse 
van de totale verkoopcijfers van antibiotica voor 
dieren en inzicht in de trends in gebruik per diersoort. 
De resultaten kunnen worden gebruikt door het 
Ministerie van Economische zaken, Landbouw en 
Innovatie, de opdrachtgever van deze studie, voor het 
meten van het effect van het beleid. Bovendien 
kunnen deze gegevens een belangrijke rol spelen in 
het verklaren van trends in de resistenties in bacteriën 
uit landbouwhuisdieren. Tevens kunnen de gegevens 
worden gebruikt voor het informeren van de Europese 
Commissie. 
 
Trends in de totale verkoop van antibiotica in 
Nederland  
Het therapeutisch gebruik van antibiotica op 
voorschrift van een dierenarts uitgedrukt in gram per 
kg levend gewicht is verdubbeld in 2007 vergeleken 
met 1999, maar is gedaald in 2008 en 2009. In 
dezelfde periode zijn de antimicrobiële 
groeibevorderaars eerst gedeeltelijk verboden en vanaf 
2006 volledig. Uit recente cijfers blijkt dat in 2010 de 
verkopen verder gedaald zijn, met 12%. 
 
Tendensen in de blootstelling aan antibiotica in 
Nederland  
De cijfers over blootstelling van dieren aan antibiotica 
in Nederland, uitgedrukt in dagdoseringen per dierjaar 
geven de volgende tendensen te zien in de jaren 2005 
tot 2009:  
 zeugen/biggen bedrijven: jaarlijkse variatie, 
afname in 2008, toename in 2009; 
 vleesvarkensbedrijven: toename in gebruik van 
2005 tot 2008, substantiële afname in 2009;  
 vleeskuikenbedrijven: toename in gebruik van 
2005 tot 2008, gelijkblijvend gebruik in 2009;  
 vleeskalverbedrijven: afname in gebruik van 
2007-2009;  
 melkveebedrijven: toenemend gebruik van 2005-
2008, afname in 2009.  
 
In de meeste sectoren lijkt het gebruik in 2009 te zijn 
afgenomen. Het gebruik bij vleesvarkens was in 2008 
statistisch significant hoger dan het gebruik in 2005. 
Ook het gebruik bij vleeskuikens was in 2008 
statistisch significant hoger dan het gebruik in 2005. 
Desondanks kan niet met zekerheid worden 
geconcludeerd dat het gebruik in een bepaalde sector 
toe- of afgenomen is, omdat de waargenomen 
verschillen in gebruik tussen 2008 en 2009 niet 
statistisch significant waren. 
 
 
Trends in resistentie 
Salmonella 
In 2009 waren  Salmonella Enteritidis en S. 
Typhimurium opnieuw de meest voorkomende 
humane serotypen, vertegenwoordigd door 33,0% en 
32,6% van alle Salmonella isolaten die in 2009 naar 
het RIVM in Bilthoven zijn gestuurd voor sero-, en 
faagtypering. S. Typhimurium werd ook regelmatig 
gevonden bij varkens (15,4%) en rundvee (17,4%), 
maar werd in 2009 niet bij pluimvee aangetroffen. 
Opvallend was verder de daling van de fractie van de 
multiresistente DT104 ten opzichte van voorgaande 
jaren, zowel bij mens als dier. In plaats daarvan is een 
opmars te zien van S. enterica subspecies enterica 
1,4,5,12: i: -, ook in andere Europese landen. Deze 
monofasische  variant betreft bijna altijd S. 
Typhimurium (EFSA expert opinion) en besloeg in 
2009 7,0% van alle humane en 11,9% van de 
varkensisolaten in Nederland. Ook het 
resistentiepatroon vertoont overeenkomsten, met een 
hoge mate van resistentie tegen ampicilline, 
tetracycline, streptomycine en sulfamethoxazole.  
Van de isolaten afkomstig van dierlijk 
monstermateriaal was S. Dublin opnieuw veruit de 
meest voorkomende serovar bij rundvee (59,8%) en S. 
Java bij pluimvee (41,5%), met name vleeskuikens. In 
vergelijking met voorgaande jaren werd S. Enteritidis 
vaker geïsoleerd, zowel in vleeskuikens als in 
pluimveevlees. In pluimvee werd verder regelmatig S. 
Gallinarum aangetroffen als gevolg van een aantal 
uitbraken onder pluimvee in Nederland in 2009. 
 
Regelmatig werd resistentie aangetroffen tegen de 
antimicrobiële groep van fluoroquinolonen, eerste 
keuze voor de behandeling van salmonellose bij de 
mens. Van alle Salmonella isolaten vertoonde 12,3% 
verminderde gevoeligheid voor ciprofloxacin, met 
grote verschillen tussen serovar of faagtype en 
diersoort waaruit de Salmonella werd geïsoleerd. Over 
het algemeen kwam ciprofloxacin resistentie vaker 
voor in S. Enteritidis dan in S. Typhimurium, terwijl in 
S. Enteritidis van humane oorsprong hogere 
resistentieniveaus werden gevonden in vergelijking 
met die uit Nederlands pluimvee. Deze laatste 
bevinding duidt op een alternatieve bron van infectie 
voor de mens (reizen, ei-importen). 
Hoewel nog steeds op een laag niveau werd ook in 
2009 resistentie aangetroffen tegen de derde en vierde 
generatie cefalosporinen, indicatief voor ESBL 
producerende salmonella’s. In totaal werden 33 
cefotaxime resistente stammen gevonden , waarvan er 
22 afkomstig waren uit dieren of vlees, vijf uit 
humaan monstermateriaal, één uit een kruidenmonster, 
terwijl van vijf de oorsprong niet was vermeld. Van 
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alle ESBL verdachte isolaten behoorden 22 (67%) tot 
S. Java. Voor zover de herkomst van deze stammen 
bekend was waren ze alle afkomstig uit pluimvee. 
 
Campylobacter 
Hoogste resistentiepercentages in Campylobacter uit 
dierlijk monstermateriaal werd gevonden tegen 
tetracycline (45,4%), ampicilline (40,2%) en de 
quinolonen (37,1% voor ciprofloxacin en 38,1% voor 
nalidixinezuur). Resistentie tegen tetracycline 
verschilde per diersoort, met hoogste resistentie in 
vleeskalveren (70% voor C. jejuni en 96,8% voor C. 
coli). Onder C. jejuni uit humaan monstermateriaal 
was 26,5% tetracycline resistent. Van de humane 
isolaten vertoonde 53,2% resistentie tegen 
ciprofloxacin, een verdere stijging ten opzichte van 
voorgaande jaren. Daarentegen daalde de 
ciprofloxacin resistentie bij vleeskuikens van 63,3% in 
2008 naar 42,6% in 2009.  
Opnieuw werd in C. coli een opvallend laag 
resistentiepercentage gezien tegen de quinolonen bij 
varkens (5,1%) in vergelijking met de percentages in 
C. coli uit pluimvee en rundvee (tot 74,2% in 
vleeskalveren).  
Resistentie tegen macrolide antibiotica werd vaker 
waargenomen in C. coli (17,7%) dan in C. jejuni 
(2,1%). Opvallend is het hoge resistentiepercentage in 
C. coli uit vleeskalveren, waarbij 25,8% van de 
isolaten resistentie vertoonden tegen erythromycine, 
claritromycine en tulathromycine. Daarentegen was 
1,3% van de humane isolaten resistent tegen 
erythromycine.  
Overigens dient vermeld te worden dat de humane 
streeklaboratoria voornamelijk gebruik maken van de 
disk diffusie methode. Aangezien de disk diffusie niet 
is gestandaardiseerd en goed gedefinieerde 
interpretatieve criteria ontbreken, kan dit resulteren in 
verschillen in resistentiepercentages tussen humane en 
dierlijke isolaten,.  
 
Shiga-toxine producerende E. coli O157 (STEC) 
Resistentiepercentages van Shiga toxine producerende 
E. coli O157 uit humaan materiaal zijn traditioneel 
laag. Na een onverklaarbare stijging in 2008, waren de 
resistentiepercentages in 2009 weer als vanouds. 
Hoogste resistentiepercentages werden gezien voor 
streptomycine en sulfamethoxazole (beide in 9,5% van 
de humane isolaten). Zoals verwacht werd resistentie 
vaker gezien in isolaten van runderen, met name tegen 
streptomycine (32%), sulfamethoxazole (20%) en 
tetracycline (17,3%). Onder Shiga-toxine 
producerende E. coli O157 werden geen ESBL 
verdachte isolaten gevonden.  
 
Commensale bacteriën E. coli en Enterococcus 
species 
Het voorkomen van antimicrobiële resistentie bij 
commensale bacteriën uit het darmkanaal weerspiegelt 
de selectiedruk als gevolg van het gebruik van 
antibiotica in dieren, met name in de tijd. 
Resistentiespercentages in E. coli en Enterococcus 
species van varkens, rundvee, pluimvee en hun vlees 
worden gebruikt als indicatie van het vóórkomen van 
resistentie determinanten in de bacteriële populatie in 
landbouwhuisdieren. 
 
In E. coli is sinds een aantal jaren sprake van een 
toename in resistentie voor de meeste antibiotica 
klassen. Deze trend zet zich voort in 2009. Met name 
de toename in resistentie tegen beta-lactam antibiotica 
is verontrustend. Cefotaxime resistentie, indicatief 
voor ESBL producerende E. coli werd aangetroffen bij 
alle voedselproducerende diersoorten, variërend van 
1,5% in melkvee tot 17,9% bij vleeskuikens. 
De enterokokken, afkomstig uit voedselproducerende 
dieren en vlees, lieten een hoge mate van resistenties 
zien tegen tetracycline (92,8% in E. faecalis, 71,1% in 
E. faecium) en erythromycine (69,6% voor E. faecalis, 
56,7% voor E. faecium). Ook resistentie tegen 
streptomycine werd vaak gezien (51,0% voor E. 
faecalis, 41,9% voor E. faecium). Opvallend was 
verder de toename van de resistentie tegen ampicilline 
bij E. faecium-isolaten van varkens, vleeskuikens en 
vleeskalveren.  
Vancomycine resistentie werd incidenteel gevonden in 
E. faecium (1,0%).  
 
 
Conclusies en aanbevelingen 
Na een periode van voortdurende toename van het 
therapeutisch antibioticagebruik bij 
landbouwhuisdieren in Nederland, is de totale 
hoeveelheid verkochte antibiotica, uitgedrukt per kg 
levend gewicht, in 2008 en 2009 gedaald. Ook de 
steekproefgegevens over het antibioticagebruik in 
specifieke diersoorten laten in drie van de vijf 
onderzochte dierlijke productiesectoren in 2009 een 
daling van het gebruik zien. 
 
Over het algemeen was in 2009 het niveau van 
antimicrobiële resistentie bij ziektekiemen in voedsel 
en commensale organismen in het maag-darmkanaal 
van voedselproducerende dieren stabiel of vertoonde 
een stijgende tendens. ESBL-verdachte Salmonella-
isolaten waren afkomstig uit verschillende bronnen, 
maar voornamelijk uit vleeskuikens. Ook E. coli 
isolaten waarvan vermoed wordt dat ze in staat zijn tot 
ESBL-productie werden gezien in alle 
voedselproducerende diersoorten, maar met name bij 
pluimvee. ESBL-producerende E. coli zijn 
aangetroffen in alle niveaus van de pluimveeproductie 
piramide, duidend op verticale transmissie. 
 
Gebaseerd op de gegevens in dit verslag kan worden 
aanbevolen dat:  
 Een gedetailleerde en onafhankelijke monitoring 
van het veterinair gebruik van antibiotica blijft 
van belang voor een goed inzicht in de 
daadwerkelijke blootstelling op diersoortniveau. 
Inzicht in de blootstelling is noodzakelijk om de 
relatie te kunnen leggen met de ontwikkeling van 
resistentie. 
 In alle lidstaten van de EU zal in de komende 
jaren een vergelijkbare en uniforme monitoring 
moeten worden opgezet, in eerste instantie 
gebaseerd op landelijke verkoopcijfers. Binnen de 
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EU zal tevens een uitbreiding van deze 
monitoring naar gegevens over de blootstelling 
op diersoortniveau moeten worden nagestreefd. 
 In het kader van de volksgezondheid blijft 
monitoring van antimicrobiële resistentie een 
essentieel instrument om inzicht te krijgen in het 
ontstaan en de ontwikkeling van resistentie bij 
dieren.  
 Het voorkomen van Salmonella en E. coli met 
resistentie tegen derde-generatie cefalosporinen 
in alle voedselproducerende diersoorten en de 
bewezen genetische verwantschap van pluimvee 
isolaten met isolaten uit humane infecties, 
rechtvaardigt een continue monitoring van de 
genetische kenmerken van de organismen in 
zowel dier als mens.  
 
 
Maran 2009 
 
 
 10 
  
Maran 2009 
 
 
 11 
I  Usage of antibiotics in animal husbandry in the Netherlands 
 
 
 
1. Introduction 
 
 
Aim 
The objective of this study is to obtain detailed insight 
into the exposure of farm animals to antibiotics, by 
monitoring both sales data at the national level and 
more specifically data per animal species. The results 
from the study can be used by the Ministry of 
Economic Affairs, Agriculture and Innovation to 
measure the effect of policy. In addition, the usage 
data can play an important role in explaining trends in 
resistance that have become apparent. Moreover, these 
data can be used to inform the European Commission. 
 
Monitoring in the Netherlands 
Since 1998 FIDIN, the federation of the Dutch 
veterinary pharmaceutical industry, annually reports 
antibiotic sales figures in the Netherlands (FIDIN, 
2010). The sales figures stated in the reports give an 
impression of the total amount of active substances 
used in the Netherlands at the level of 
pharmacotherapeutic groups. Moreover, the 
monitoring of antibiotic use on a stratified sample of 
Dutch farms provides information about the true 
exposure of farm animals to antibiotics, and into the 
underlying factors that could explain changes in 
antibiotic use. The use in veal calves has been 
monitored in an additional sample, in cooperation with 
the veal calf sector. 
Monitoring in Europe 
All EU member states are required to monitor 
antimicrobial resistance in food producing animals of 
public health concern (Zoonosis Directive 
2003/99/EC). Within this context, monitoring of 
antibiotic usage is equally important. Therefore the 
European Medicines Agency (EMA) is carrying out 
the ESVAC project to establish national systems for 
the collection of data on sales of veterinary 
antimicrobial agents in Europe, in a standardized way 
(EMA, 2010). ESVAC stands for European 
Surveillance of Veterinary Antimicrobial 
Consumption. The project was set up in April 2010 to 
collect information on how antimicrobial medicines 
are used in animals across the European Union. The 
EMA started this project following a request from the 
European Commission for the Agency to develop a 
harmonised approach for the collection and reporting 
of data on the use of antimicrobial agents in animals 
from the EU Member States. EC Directive 
2001/82/EC and Regulation 726/2004 provide a legal 
basis for national authorities to request the 
pharmaceutical industry to provide data on sales of 
antimicrobial agents. However, member states are not 
yet obliged to provide data about the use of veterinary 
antibiotics to the EC. 
 
 
 
Table 2.1. Trends in livestock in the Netherlands in numbers (thousands)1 
 
Source: Eurostat 2010 
  
                                                     
1 Other pigs is a calculated number (statistical adjustment). 
Number of animals * 1.000 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Piglets (less than 20 kg) 4,791 4,935 4,422 4,225 3,896 4,300 4,170 4,470 4,680 4,555 4,809
Sows 1,320 1,272 1,161 1,140 1,052 1,125 1,100 1,050 1,060 1,025 1,100
Fattening pigs (of at least 50 kg) 4,668 4,560 5,911 5,772 5,807 5,705 5,715 5,880 5,960 6,135 6,192
Other pigs 2,360 2,055 20 17 11 10 15 -180 10 20 7
Turkeys 1,544 1,544 1,523 1,451 1,112 1,238 1,250 1,200 1,250 1,250 1,356
Other poultry 54,506 54,506 48,642 48,714 43,168 44,427 45,800 45,475 45,050 46,958 48,865
Veal calves 800 756 676 692 748 775 813 824 860 913 886
Cattle (veal calves excluded) 3,297 3,134 3,166 3,088 2,986 2,984 2,933 2,849 2,960 3,083 3,112
Sheep 1,152 1,250 1,250 1,300 1,476 1,700 1,725 1,755 1,715 1,545 1,099
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Table 2.2. Trends in livestock in the Netherlands in live weight (tonnes) 
 
 
 
 
2. Materials and methods 
 
 
2.1 Method used for analysis of sales data 
The FIDIN report presents the total number of 
kilograms of antibiotics (active ingredient) sold in the 
Netherlands at the level of pharmacotherapeutic 
groups. The data about use of active substances are 
based on sales data of members of FIDIN and are 
estimated to cover about 98% of all sales. Actual use 
can be different from the amounts sold as a result of 
stock piling and cross border use. The figures give 
information about the total sales for all animals, not 
per individual animal species. 
The total sales figures published by FIDIN have been 
related to the number and total live weight of animals 
in the Dutch livestock farming sector (pigs, poultry, 
veal calves, other cattle, sheep). For this analysis the 
following average weights have been used: veal calves 
(weighted average of white and rosé) 176 kg, other 
cattle 500 kg, turkeys 6 kg, other poultry 1 kg, 
fattening pig 70 kg, sow 220 kg, other pigs 70 kg, 
piglets (< 20 kg) 10 kg, sheep 60 kg. This yields 
information about the trend in the sales of antibiotics 
in grams per kilogram of live animal weight over the 
years, thus taking yearly fluctuations in the size of the 
animal population into account. 
The yearly average numbers of animals present in the 
Netherlands (Table 2.1) are converted into live weight 
(Table 2.2). To obtain insight into the trends in 
antibiotic usage based on the national sales data, the 
total antibiotic sales are divided by the total live 
weight of the average present livestock (see Figure 
3.1). 
 
2.2 Method used for analysis of usage data on 
farms in the Farm Accountancy Data Network 
This report reviews the antibiotic usage in 2009, and is 
based on a total of 231 pig, broiler and dairy cattle 
farms in the Farm Accountancy Data Network. The 
results about veal calves are based on 193 farms in a 
large additional sample. See Table 2.3 for details. 
 
The Data Network contains a representative sample of 
around 1,500 agricultural and horticultural farms in 
the Netherlands (Vrolijk et al, 2009). Records are 
made of the economic data and technical key figures 
of these farms. Every year a number of farms are 
replaced by other farms to ensure that the database of 
the Data Network remains representative for Dutch 
livestock farming. On these farms all animal-medicine 
data and veterinary services are recorded. The data for 
the veal calves originate from an additional aselect 
sample of all veal calf farms. On these farms detailed 
data were collected on number of animals present and 
the amount of antibiotics used. 
 
These data are available on the websites of LEI 
(www.lei.wur.nl and www.maran.wur.nl) and CVI 
(www.cvi.wur.nl). They provide further insight into 
the use of antibiotics expressed as the number of daily 
dosages per animal year and about the use in grams of 
active ingredients per animal year. Note that the data 
only apply to the farms in the sample(s). The 
aggregated usage data with 95% confidence intervals 
are considered to be representative for the total 
exposure of Dutch food-producing animals to 
antibiotics. The 95% confidence intervals indicate that 
with 95% certainty, the average antibiotic use on a 
national level, expressed in terms of the number of 
daily dosages per animal year, will lie within the 
upper and lower limits given. 
 
 
  
kg live weight *1.000 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Pigs 831,204 793,152 715,992 699,434 678,786 691,691 685,943 675,876 699,092 703,127 725,258
Turkeys 9,264 9,264 9,138 8,706 6,672 7,428 7,500 7,200 7,500 7,500 8,135
Other poultry 54,506 54,506 48,642 48,714 43,168 44,427 45,800 45,475 45,050 46,958 48,865
Veal calves 141,040 133,283 119,179 122,000 131,943 136,633 143,332 145,271 151,618 160,962 156,202
Cattle (veal calves excluded) 1,648,500 1,567,000 1,583,000 1,544,000 1,493,150 1,492,000 1,466,500 1,424,500 1,480,000 1,541,500 1,556,000
Sheep 69,120 75,000 75,000 78,000 88,560 102,000 103,500 105,300 102,900 92,700 65,940
Total 2,753,634 2,632,205 2,550,951 2,500,854 2,442,279 2,474,179 2,452,575 2,403,622 2,486,160 2,552,747 2,560,401
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Table 2.3. Number of sample farms taking part each year and the associated number of animals 
 
n.a. = no data available 
 
 
 
2.3 Unit of measurement: number of daily doses 
per animal year 
To provide insight into the true exposure of animals to 
antibiotics the use is expressed in the number of daily 
doses per animal year: ADD (Jensen et al, 2004). 
Antibiotics vary in their potency and pharmacokinetic 
properties2, and this results in different dosages per 
kilogram body weight between and within antibiotic 
classes. Because of these differences the unit “grams 
per kg live weight”, as calculated from total sales 
figures, is a less accurate indicator for the use of 
antibiotics. The unit “daily dosage” is more suitable 
for calculating the exposure of animals to antibiotics. 
Adopting this approach offers an opportunity to obtain 
more insight into the relationship with the occurrence 
and trends in resistance. Moreover, this unit conforms 
to international developments in this field and 
developments in the human health sector. The broader 
implementation of records of this nature will also 
improve the feasibility to compare for example the 
antibiotic use in different EU member states in similar 
livestock systems. 
The number of daily dosages per animal year was 
determined by calculating the total number of 
kilograms of animal that can be treated with each 
active ingredient: the treatable weight. This was then 
divided by the total weight of the average present 
livestock on the farm3. This assumes that the average 
treatment is administered to animals with an average 
weight. With this approach the calculation and 
comparison of the total antibiotic use on farms is 
                                                     
2Differences in dosage are determined by differences in potency, 
differences in bioavailability and distribution throughout the 
body. 
3This is the average weight of the animals (in kg per animal) 
multiplied by the average number of animals present on the farm 
per year.Note that on dairy farms only the weight of the dairy 
cows has been taken into account. 
possible, even when different active ingredients are 
involved. Expressing the use per animal year enables 
comparisons of farms with different vacancy periods. 
However, especially in some sectors (e.g. veal calves) 
differences in length of production periods should also 
be taken into account. 
This information can then be used to obtain an insight 
into the total antibiotic use for specific animal species 
and categories of animal species (for example, 
fattening pigs) on a specific group of farms (for 
example, all pig farms with fattening pigs). This is 
expressed in terms of an average number of daily 
dosages per animal year for fattening pigs. More 
information about this unit of measurement is given in 
the following daily dosages box, which also includes 
an example of a calculation. The use of antibiotics in 
spray containers is not included. 
 
Animal weights 
In general younger animals are more likely to 
encounter health problems than older animals, while 
animals no longer receive antibiotics in the last period 
before slaughter, primarily because of less health 
problems and also to ensure that the meat is free of 
antibiotic residues. The best estimation of the total 
treatment duration per year would be obtained by 
calculating the number of daily dosages on the basis of 
the best possible estimate of the average weight at the 
time of treatment. However, the information currently 
available is not sufficient to determine the exact 
weight of the animals at the time of the administration 
of the medicine. For this reason the calculations in this 
report are still based on the average weight per animal 
during the animals’ presence on the farm. The 
calculated number of defined daily dosages is 
therefore expected to be an underestimation of the true 
exposure, especially for piglets, fattening pigs and 
veal calves. 
2005 2006 2007 2008 2009
Sows/piglets 16790 12155 17949 18767 20806
Fattening pigs 54788 55970 119922 156098 159104
Broilers 2367623 2315882 2197716 2508103 2530313
Veal calves n.a. n.a. 124096 134437 134446
Dairy cows 2875 2818 2850 7274 7382
Sows/piglets 46 32 39 45 48
Fattening pigs 40 31 49 77 72
Broilers 29 28 29 29 28
Veal calves n.a. n.a. 185 199 193
Dairy cows 35 34 34 82 83
150 125 336 432 424
Type of holding
Number of 
animals
Number of 
farms
 Total
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In the sample survey the following average weights 
have been used: dairy cows 600 kg, veal calves 176 kg 
(i.e. the weighted average of white veal calf 164 kg 
and rosé veal calf 192 kg), broilers 1 kg, fattening pigs 
70.2 kg, sows 220 kg, maiden gilts 107.5 kg, piglets 
(< 25 kg) 12.5 kg, breeding boars 350 kg (ASG, 
2010). On dairy farms the number of daily dosages is 
based on the weight of the dairy cows only, because 
this category of the animals gets almost all of the 
antibiotics. However, on sow farms the size of the 
‘population at risk’ is based on the weight of all 
present animals (including piglets, gilts, breeding 
boars).For an illustrative calculation of the number of 
daily dosages for young calves on dairy farms (from 
birth to weaning at 56 days of age) the average weight 
of 56.5 kg has been used. 
 
 
 
Daily dosages  
 
The amounts of different active ingredients cannot simply be totalled since the antimicrobial potency and 
pharmacokinetics (and, consequently, the dosage prescription) varies between active ingredients. However, active 
ingredients can be compared and totalled once the active ingredient in each antibiotic preparation is expressed in terms 
of the daily dosage. The daily dosage is a measure of the number of milligrams of a specific active ingredient required 
to treat one kilogram of animal in one day with that antibiotic preparation, and is based on the recorded average dosage 
of a medicine for a specific type of animal4. These daily dosages can be totalled to determine the total exposure to 
antibiotics. The daily dosages are specific to the type of animal, and have been defined for dairy cattle, veal calves, 
pigs and poultry. Consequently, antibiotic preparations may have been assigned multiple daily dosages, according to 
the type of animal the preparations are administered to, i.e. the daily dosage for each type of animal. 
 
Example of a calculation of the daily dosage 
For example, a farm with 150 fattening pigs with an average weight of 70.2 kg used 2 litres of antibiotic preparation X 
during the course of one year (X contains 40% = 400 mg/ml active ingredient a) and 20 kg of antibiotic preparation Y 
(Y contains 25% = 250 mg/g active ingredient b). Antibiotic preparation X: the defined daily dosage of active 
ingredient a is 10 mg per kg animal weight per day. Antibiotic preparation Y:the defined daily dosage of active 
ingredient b is 50 mg per kg animal weight per day. 
 
Antibiotic X can be used to treat (2,000 * 400)/10 = 80,000 kg animal weight. Antibiotic Y can be used to treat 
(20,000 * 250)/50 = 100,000 kg animal weight. Consequently, the farm has used antibiotics for treatment of a total of 
180,000 kg animal weight. The farm has an average of 150 fattening pigs per year, with a total weight of 10,530 kg. 
180,000 kg were treated in that year, equivalent to 180,000/10,530 = 17.1 daily dosages. Consequently, an average 
fattening pig5 on the farm in that year was administered a prescribed dosage of antibiotics on 17.1 days. In this 
example the farm uses 17.1 daily dosages per animal year of antibiotic preparation X plus Y. 
 
 
 
                                                     
4 For veal calves the calculated daily dosages are based on the highest allowed dosage instead of the average dosage. This is according daily 
practice where usually the highest recorded dosage is administered. The use per average veal calf is calculated on the basis of the 
composition of the veal calf sector in the Netherlands: 70% white veal calves and 30% rosé veal calves. 
5This refers to a pig on the farm throughout the year: however, there is no such pig. This is a method which can be used to provide for 
comparisons of farms with different vacancy rates. For example, a farm has 2 herds of animals a year, both of which comprise 200 animals 
that remain on the farm for 5.5 months. The farm is vacant during the first and last week of the year, and for 2 weeks between the two herds. 
The calculations for this farm are based on an average of 183 animals present on the farm. When a farm is vacant for six months and has a 
herd of 200 animals for six months then the calculations are based on an average of 100 animals on the farm. 
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2.4  Statistical analysis 
To obtain insight into the amount of and trends in 
antibiotic use on the national level, the sample of 
farms in FADN and the additional sample for veal 
calves are used to estimate the usage in the whole 
population (average use per average animal present on 
an average farm). 
 
This limited number of farms used may affect the 
validity of the conclusions drawn for the whole 
population. However, the selection of farms in the 
sample should be representative for the different 
animal production sectors. In this way a sample can 
provide adequate information (Vrolijk et al, 2009). 
Because of the observed large variation in use of 
antibiotics between individual farms in the sample 
relatively large sample sizes are necessary to make 
reliable estimates for the whole population. 
 
To ensure that the farms that are included in the 
sample are representative of the whole population and 
to make the sampling as efficient as possible a 
disproportional stratified random sampling strategy is 
used. A stratified sample implies that the population is 
divided into a number of homogeneous groups. 
Subsequently farms are selected from each of the 
groups. For strata with larger variation in the use of 
antibiotics, relatively more sample farms are selected. 
In the FADN sample the strata are based on both farm 
size and animal category. The additional sample of 
veal calf farms is additionally stratified for ‘large 
integration’ versus ‘small integration or non-
contracted farms’. 
Since the stratification is disproportional, the results 
have to be weighted to be representative. For each 
stratum the average daily dosages per animal year is 
determined. Then the weighted average for an animal 
category is calculated, based on the number of farms 
in the population in each stratum. 
 
In this report the usage data of all sample farms are 
used to present the findings about the use of 
antibiotics and also for further statistical analysis 
about decrease of increase of antibiotic use over a 
period of two or more years. Comparing means 
between two years can be done in two ways, either by 
only using farms that are in the sample for both years6 
or by comparing the means independently, using all 
sample farms in both years. The first method usually 
gives better results if the number of sample farms 
available in both periods is not much smaller that the 
number of farms in the separate years. This usually is 
the case in subsequent years. However, if the years of 
comparison are further apart, the number of sample 
farms available in both years will be more limited. 
Additionally, the direction of the change might even 
be different from the direction in the total sample. In 
that case, testing for significant differences can better 
be done by using the means and standard errors of the 
separate years instead of using a subsample. If the 
                                                     
6See Appendix 3 in Vrolijk et al. (2008) for more detail about 
the statistics. 
difference between the two means is larger than twice 
the square root of sum of both squares of the standard 
errors then there is a significant difference.
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3. Trends in antibiotic usage 
 
 
3.1 Trends in the total antibiotic use in the 
Netherlands 
Figure 3.1 shows the trends in the total sales of 
therapeutic antibiotics in the Netherlands. The figure 
was prepared from total sales figures presented by 
FIDIN (FIDIN, 2010). Table 3.1 shows the use 
specified per group of antibiotics, including the use of 
antimicrobial growth promoters (AGP). 
 
 
 
Figure 3.1. Veterinary therapeutic antibiotic sales from 1999-2009 (FIDIN, 2010; vertical bars). The line 
presents the trends in grams of active ingredients used per kg live weight. 
 
 
 
 
Figure 3.1 reveals that the total amount of antibiotics 
sold by the pharmaceutical industry in the Netherlands 
for therapeutic veterinary use has increased in the 
period 1998-2007. Compared to 2007 in 2008 the 
amount of antibiotics sold has decreased by 10% and 
in 2009 by a further decrease of 2%. Recently FIDIN 
reported a further reduction of 12% of veterinary 
antibiotic sales in 2010, to 455 tonnes. We consider 
this reduction to be the result of the efforts of the 
animal production sectors and the authorities that take 
part in the Task Force Antimicrobial Resistance in 
Animals. 
 
The use of antimicrobial growth promoters was 
prohibited at the beginning of 2006. Apart of the 
increase of therapeutic antibiotic use in the years 
1998-2006 may be accounted for by a substitution of 
growth promoters. See Table 3.1 for the quantitative 
figures about the use of AGP. 
 
Over the years, the number of the livestock has also 
changed. The trends in therapeutic antibiotic use in 
relation to the number and weight of animals in the 
Netherlands are presented in Figure 3.1. 
 
 
 
Table 3.1. Antibiotic sales from 1999-2009 in tonnes (FIDIN, 2010) 
 
 
  
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Penicillins /cephalosporins 37 38 40 40 38 45 54 60 64 74 79
Tetracyclines 171 204 211 225 227 269 307 317 338 271 268
Macrolides 10 16 18 20 18 24 29 44 58 55 51
Aminoglycosides 13 12 11 10 9 9 11 11 12 11 10
Fluoroquinolones 7 7 6 6 5 7 8 7 9 8 8
Trimethoprim/sulfonamides 73 82 94 94 90 93 93 95 101 102 95
Other 11 12 11 11 7 6 6 8 8 7 8
Total therapeutic use 322 371 391 406 394 453 508 542 590 529 518
Antimicrobial growth promoters (AGP) 250 205 180 140 120 80 40 0 0 0 0
Antibiotic use including AGP 572 576 571 546 514 533 548 542 590 529 518
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3.2 Trends in exposure to antibiotics in the 
Netherlands 
Figure 3.2 shows the tendencies in exposure to 
antibiotics in defined daily dosages per average animal 
present per year (ADD) in the five sectors examined in 
this study, based on the farms in the samples. The 
outcome of the calculations is indexed, using 2009 as 
baseline year. The continuous line represents the 
calculated average use. The 95% confidence intervals, 
calculated as from 2005 (indicating that with 95% 
certainty, the average antibiotic use on a national 
level, expressed in terms of the number of daily 
dosages per animal year, will lie within the upper and 
lower limits) are indicated by the dotted lines shown 
in Figure 3.2.  
 
 
 
 
 
Figure 3.2 Tendencies in relative antibiotic usage from 2005-2008 in percentages daily dosages per animal 
year at the sample farms in 2005-2009 (daily dosages per animal year in 2009 = 100%). For veal calves data are 
available as from 2007. 
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Figure 3.2 shows different tendencies in exposure to 
antibiotics in the different animal species, indicating a 
decrease in antibiotic use in most animal production 
sectors in 2009: 
 sow/piglet farms: annual variation, slight 
decrease in 2008, increase in 2009; 
 fattening pig farms: increased usage from 2005 to 
2008, followed by a substantial decrease in 2009; 
 broiler farms: increased usage from 2005 to 2008, 
usage remained stable in 2009; 
 veal calf farms: decreased usage from 2007 to 
2009; 
 dairy farms: increased usage from 2005 to 2008, 
decrease in 2009. 
The usage in fattening pigs in 2008 was statistically 
significantly higher than the use in 2005. Also the 
usage in broilers in 2008 was statistically significantly 
higher than the use in 2005. 
 
It is important to note that in spite of the variation 
presented, the data in figure 3.2, representing the use 
of antibiotics at the farms in the sample, do not permit 
a distinct conclusion that the use in specific sectors in 
the Netherlands has increased or decreased in 
consecutive years. None of the differences between 
consecutive years were statistically significant. This is 
primarily due to the observed differences in use 
between the farms (large variation) in combination 
with a limited number of farms in the sample. The 
relatively small confidence interval for veal calves is a 
favorable consequence of less variation, strengthened 
by a relatively large sample size. The monitoring in 
the veal calf sector started in 2007. 
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4. Antibiotic usage per animal species in 2009 
 
 
4.1 Pigs 
 
Sows and piglets 
In 2009, the average animal on sow/piglet production 
farms in this survey received approximately 25 daily 
dosages per year. More than 80% was orally 
administered, probably predominantly in piglets. The 
average use in the sow/piglet sector in the Netherlands 
will be at most 19% higher or lower than the average 
determined at the sample farms (95% Confidence 
Interval: 21-30 dd/ay). This large confidence interval 
is mainly caused by the large variation in use that 
exists between different farms. 
 
Figure 4.1 provides insight into the trends in the 
relative use of the various groups of antibiotics on the 
sample farms 
 
 
 
Figure 4.1. Antibiotic use in sows/piglets in daily dosages per sow per year in 2005-2009 
 
 
 
 
In 2009 40% of the total antibiotic use in sows/piglets 
consisted of tetracyclines, 22% of 
trimethoprim/sulfonamides and another 21% of 
penicillins. 0.7% of the total usage consisted of 3rd and 
4th generation cephalosporins and 0.2% consisted of 
fluoroquinolones, that are likely to have been 
administered to young piglets before weaning. 
 
Discussion 
We observe a tendency to reintroduce conservative 
therapy with traditional antibiotic groups 
(tetracyclines, trimethoprim/sulfonamides) instead of 
introducing newer antibiotics like cephalosporins, 
fluoroquinolones and macrolides. 
 For sows/piglets in the sample the average use 
in 2009 was 25 daily dosages per year. However, in 
practice almost all of the antibiotics are likely used for 
the treatment of the piglets, and only incidentally for 
the sows. If it is assumed that 100% of the antibiotics 
are administered to the piglets, with an average weight 
of 12.5 kg, this would mean that an average piglet is 
treated with antibiotics during 25 days in the period 
from birth to the age of 74 days (at delivering to the 
fattening farm, at 25 kg). 
 
The findings reveal a positive correlation between the 
size of sow farms and the antibiotic use per animal, as 
shown in table 4.1 below. Note that the figures in the 
table are mean values. On a quarter of the farms with 
more than 250 sows the usage of antibiotics was under 
20 daily dosages per animal year. 
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Table 4.1 Number of daily dosages per animal year for different farm sizes 
 
 
 
 
Fattening pigs 
The average fattening pig in the sample received 
16 daily dosages per year in 2009, of which nearly 
97% orally administered. The average use on pig 
fattening farms in the Netherlands will be at most 28% 
higher or lower than the average determined at the 
sample farms (95% Confidence Interval: 11-20 dd/ay). 
 
Figure 4.2 provides insight into the trends in the 
relative use of the various groups of antibiotics on the 
sample farms
 
Figure 4.2. Antibiotic use in fattening pigs in daily dosages per animal year in 2005-2009 
 
 
 
 
In 2009 70% of the total antibiotic use in fattening 
pigs originated from the administration of 
tetracyclines and 13% from macrolides/lincosamides. 
Cephalosporins and (fluoro)quinolones were not 
applied. 
 
Discussion 
The average fattening pig in the sample was treated 
with antibiotics 16 days per year. Assuming a 
production period of 117 days, 5 daily dosages (= 16 x 
(117/365) are administered to each fattening pig 
during its production period from 25 kg to slaughter 
weight. This average fattening pig has also received 
antibiotics at the breeding farm (during 25 days), 
which brings the total exposure to antibiotics per 
average fattening pig to approximately 30 days during 
its whole life from birth to slaughter at the average age 
of 191 days. 
 
If it is assumed that the average treatment weight of 
fattening pigs will be thirty percent lower than their 
average live weight, since younger animals are more 
likely to receive antibiotics than older animals, the 
estimation of the total life time true exposure increases 
from 30 days to a total of 32 days. 
 
< 250 sows 250-600sows > 600 sows
Daily dosages per animal year 15 30 50
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4.2 Broilers 
The average boiler chicken in the sample received 37 
daily dosages per year in 2009, administered orally, 
mainly through the drinking water. Based on the 95% 
Confidence Interval of 24-49 dd/ay the average use on 
broiler farms in the Netherlands will be at most 34% 
higher or lower than the average determined at the 
sample farms. 
 
Figure 4.3 provides insight into the trends in the 
relative use of the various groups of antibiotics on the 
sample farms. 
 
 
Figure 4.3 Antibiotic use in broilers in daily dosages per animal year in 2005-2009 
 
 
 
 
In 2009 administration of penicillines accounted for 
39% of the total antibiotic use on broiler farms, 
intestinal anti-infectives for 18%, quinolones for 18% 
and tetracyclines for 15%. Fluoroquinolones use was 
1.4% of the total use. The use of intestinal anti-
infectives (e.g. neomycin, colistin) decreased from 9.5 
dd/ay in 2008 to 6.7 dd/ay in 2009. In the same period 
the use of penicillins almost doubled from 7.2 in 2008 
to 14.3 in 2009. 
 
Discussion 
On the average broiler farm in the sample 37 daily 
dosages of antibiotics are administered per year. This 
means that an individual broiler is treated with 
antibiotics during 4 days (= 37 x 42/365) in the 42 
days from day one to slaughter. 
 
Data on the time of prescription reveal that the 
average weight on which broilers receive treatment 
equals the average live weight of 1.0 kg. Therefore the 
calculated exposure of approximately 4 days per 
broiler can be considered as an adequate estimation of 
the true exposure (i.e. 3 to 6 treatment days per 
broiler, considering the 95% confidence interval). 
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4.3 Veal calves 
The average veal calf in the sample received 30 daily 
dosages per animal year in 2009, of which more than 
90% was orally administered. The average use on veal 
calf farms in the Netherlands will be at most 6% 
higher or lower than the average determined at the 
sample farms (95% Confidence Interval: 28-31dd/ay). 
 
Figure 4.4 provides insight into the trends in the 
relative use of the various groups of antibiotics on the 
sample farms. 
 
 
Figure 4.4. Antibiotic use in veal calves in daily dosages per animal year in 2007-2009 
 
 
 
 
In 2009 49% of the total antibiotic use on veal calf 
farms originated from the administration of 
tetracyclines, 20% from intestinal anti-infectives (e.g. 
neomycin, colistin) and 10% from 
trimethoprim/sulfonamides. Fluoroquinolones and 3rd 
and 4th generation cephalosporin use were both 1.3% 
of the total use. 
 
Discussion 
The overall use decreased, mainly as a result of less 
traditional antibiotic therapy with tetracyclines. The 
application of the newer antibiotics like 
cephalosporins, fluoroquinolones and macrolides 
seems to be unchanged, whereas a decrease was 
expected. 
 
On the average veal calf farm in the sample 30 daily 
dosages of antibiotics are administered per year. This 
means that the individual average veal calf is treated 
with antibiotics during 18 days (= 30 x 222/365) in the 
period from birth to the average slaughter age of 222 
days (white and rosé). 
 
If it is assumed that the average treatment weight of 
veal calves is about fifty percent lower than the 
average live weight, since younger animals are more 
likely to receive antibiotics than older animals, the 
estimation of the total life time true exposure increases 
from 18 days to a total of 36 days. 
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4.4 Dairy cows 
The average dairy cow in the sample received 5.8 
daily dosages per year in 2009, including the use in 
young stock. The average use on dairy farms in the 
Netherlands will be at most 12% higher or lower than 
the average determined at the sample farms (95% 
Confidence Interval: 5.1-6.5 dd/ay). 
 
Figure 4.5 provides insight into the trends in the 
relative use of the various groups of antibiotics on the 
sample farms. 
 
 
Figure 4.5. Antibiotic use in dairy cattle in daily dosages per animal year in 2005-2009 
 
 
 
 
In 2009 48% of the total antibiotic use on dairy farms 
originated from the administration of penicillins and 
19% from combinations, which were mainly 
applications for intramammary treatment. Also 13% 
third/fourth generation cephalosporins were used. Use 
of fluoroquinolones is limited in dairy cattle. 
 
Discussion 
After a couple of years of steadily increasing 
application of the newer antibiotics like 3rd and 4th 
generation cephalosporins, fluoroquinolones and 
macrolides, 2009 may represent a turning point. 
 
On the average dairy farm in the sample in 2009 5.8 
daily dosages of antibiotics were administered per 
year, of which 3.4 for intramammary use and 0.3 for 
oral use. If it is assumed that the oral use is only 
applied in young calves, an average calf is exposed to 
antibiotics during 9 days of the 56 day weaning 
period. Note that part of the antibiotics that are 
registered for oral treatment may have been used off-
label in footbaths for disinfection of cattle feet instead 
of treating sick calves. 68% of the intramammary use 
is used for drying off, which means that on average 
90% of the dairy cows has received dry cow treatment 
in all four quarters. 
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5. Conclusions 
 
The results from the monitoring provide an overview 
of the total sales of antibiotics in the Netherlands. On 
the basis of monitoring at a sample of farms there is 
also more detailed information available about the 
(trends in) exposure to various antibiotics at dairy, 
pig, broiler and veal calf farms. 
 
Trends in total sales of antibiotics in the Netherlands 
Therapeutic antibiotic use expressed in terms of grams 
per kg live weight has doubled in 2007 compared to 
1999, but has decreased in 2008 and 2009. Recent 
sales figures indicate a further decrease of 12% in 
2010. During this same period, the antimicrobial 
growth promoters have been banned, first partly and 
as from 2006 entirely. 
 
Tendencies in exposure to antibiotics in the 
Netherlands 
Figure 3.2 shows different tendencies in exposure to 
antibiotics in the different animal species for the years 
2005-2009, indicating a decrease in antibiotic use in 
most animal production sectors in 2009: 
 sow/piglet farms: annual variation, slight 
decrease in 2008, increase in 2009; 
 fattening pig farms: increased usage from 2005 to 
2008, followed by a substantial decrease in 2009; 
 broiler farms: increased usage from 2005 to 2008, 
usage remained stable in 2009; 
 veal calf farms: decreased usage from 2007 to 
2009; 
 dairy farms: increased usage from 2005 to 2008, 
decrease in 2009. 
The usage in fattening pigs in 2008 was statistically 
significantly higher than the use in 2005. Also the 
usage in broilers in 2008 was statistically significantly 
higher than the use in 2005. However, the findings do 
not permit a distinct conclusion that the use in a 
particular sector in the Netherlands has increased or 
decreased, because the observed differences in 2009 
were not statistically significant compared to 2008. 
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website at www.maran.wur.nl. 
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II Resistance data 
 
In this chapter susceptibility test results are 
presented as determined in 2009 for the food-
borne pathogens Salmonella spp., Campylobacter 
spp. and Escherichia coli O157, the food-borne 
commensal organisms E. coli, Enterococcus 
faecium and E. faecalis. 
 
 
 
6. Food-borne pathogens 
 
Salmonella  
 
Resistance percentages are presented on 
Salmonella isolated from humans suffering from 
clinical infections, food-producing animals and 
food products from animals as potential sources 
for distribution to humans via the food chain, and 
animal feeds as potential source for food-
producing animals 
 
Highlights 
 
In 2009, Salmonella Enteritidis and S. Typhimurium were again the most frequently encountered serovars in 
human samples, represented by 33.0% and 32.6% of all Salmonella sent to RIVM Bilthoven for sero-, and 
phagetyping, followed by S. enterica subspecies enterica 1,4,5,12:i:- (7.0%). This serovar, as elsewhere in 
the EU, is strongly emerging, while the relative portion of DT104 has decreased compared to previous years. 
As in previous years, S. Dublin was by far the most prevalent serovar in cattle (59.8%), followed by S. 
Typhimurium (17.4%). In pigs, S. Typhimurium was still the most common serovar in 2009 (15.4%), 
although its prevalence seems to be decreasing over the years. In 2009, S. enterica subspecies enterica 
1,4,5,12:i:- was commonly isolated, represented by 11.9% of the porcine isolates.  
S. Java is still the most important Salmonella serovar in poultry, especially in broiler chickens. In 2009, 
41.5% of all Salmonella isolates from poultry were identified as such. Noteworthy, S. Enteritidis was 
isolated more often in broiler chickens as well as in poultry meat compared to previous years. Also S. 
Gallinarum was commonly encountered in 2009, the result of several outbreaks that have occurred in poultry 
in the Netherlands. 
The resistance levels in Salmonella isolates against the clinically important fluoroquinolones, the first choice 
antimicrobial for treatment of salmonellosis in humans, differed among serovars and phage types. Generally, 
ciprofloxacin resistance was higher in S. Enteritidis than in S. Typhimurium. As in previous years, in S. 
Enteritidis of human origin resistance levels were higher compared to levels in Dutch poultry, suggesting an 
additional source of infection (travel, egg-imports). 
Also resistance against third-generation cephalosporins, the second choice antimicrobials for treatment of 
severe Salmonella infections in humans, was present in Salmonella isolates, although still at low levels. In 
2009, 33 suspected ESBL producing Salmonella isolates were found, of which 22 were isolated from 
animals and meat, 5 from human infections, 1 from spices and 5 were of unspecified origin. Of all ESBL 
producing isolates, 22 (67%) belonged to S. Java either derived from poultry or from an unspecified source. 
 
 
 
Salmonella prevalence 
In 2009 a total of 2124 Salmonella isolates were 
sent to RIVM Bilthoven for sero-, and 
phagetyping, of which 1901 were tested for 
antimicrobial susceptibility (Table 6.1 and 6.2). 
Human  isolates (N=1112) concerned a selection 
from first isolates sent to the Dutch National 
Institute of Public Health (RIVM) by the regional 
public health laboratories. All strains were the 
first isolates recovered from patients with 
salmonellosis. The majority of the isolates from 
pigs (N=227) and cattle (N=92), including calves 
were sent to the RIVM by the Animal Health 
Service from a diversity of surveillance programs 
and clinical Salmonella infections. Those from 
chickens (broilers, including poultry products, 
N=188; layers, reproduction animals and eggs, 
N=50) concerned mainly nonclinical Salmonella 
infections derived from a diversity of monitoring 
programs on farms, slaughterhouses and at retail. 
A large proportion of isolates from pigs in 2009 
concerned those from the Dutch component of 
the EU-baseline study in breeding pigs. Isolates 
from a diversity of other sources have been 
analyzed as well (animal feed and human food 
products; other animals from animal husbandry 
and pets, samples from the environment, etc.). 
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Table 6.1. Most prevalent Salmonella sero-, and phage types isolated in 2007/2008 and 2009 from 
humans, pigs, poultry, broilers and layers and the % travel related human infections from 2007 - 
2009. 
 
Typing results of the Dutch Salmonella Reference Laboratory (RIVM, Bilthoven). Isolates are from different sources and 
programs. Poultry: all chicken categories together; Broilers: including chicken products; Layers: including reproduction animals 
and eggs.  
  
Travel
>2007 07/08 2009 07/08 2009 07/08 2009 07/08 2009 07/08 2009 07/08 2009
N total 7% 2910 1220 1540 227 198 92 1139 347 809 188 136 50
N tested 2653 1112 480 53 170 73 721 221 514 106 89 39
Typhimurium 3% 31,3 32,6 22,0 15,4 23,2 17,4 4,0 3,3 7,4
ft507 1% 9,7 8,2 4,2 5,3 6,6 4,3 1,1 1,1
ft506 (DT104) 2% 8,3 5,1 4,0 3,1 5,6 3,3 1,1 0,9 2,9
ft651 2% 0,7 0,2 0,5 1,1 0,3 1,5
ft353 1% 2,0 0,4 1,1
ft561 (DT7) 0% 0,7 0,7 0,3 0,4 0,5
ft90 0% 1,7 0,1
Enteritidis 15% 35,4 33,0 2,7 3,5 2,0 1,1 8,3 14,4 4,8 12,2 28,7 28,0
Pt4 8% 8,8 7,4 0,4 0,4 2,5 2,9 1,1 3,2 11,0 2,0
Pt21 18% 6,1 4,1 0,1 0,5 0,9 4,6 0,6 4,3 2,2 12,0
Pt8 12% 6,3 5,7 0,6 1,3 1,0 1,1 1,7 1,2 1,2 1,1 2,2 4,0
Pt1 21% 3,2 3,3 0,3 0,4 0,6 0,1 1,1 1,5
Pt6 21% 2,9 4,1 0,1 0,2 0,3 0,2
Pt14b 19% 1,5 2,0 0,1 0,2 0,1 0,7
Agona 29% 0,4 0,3 1,6 1,3 1,1 0,3 1,1 0,7
Anatum 23% 0,4 2,2 1,3 0,5 0,5 0,9 0,5 1,6
Bovismorbificans 5% 0,4 0,2 2,1 5,7 1,5 0,3 0,1 1,5
Brandenburg 2% 0,5 0,3 5,5 3,5 0,5 0,1 0,6 2,0
Corvallis 29% 0,8 0,8 0,1 0,3 0,1
Derby 7% 0,4 0,7 15,3 7,9 0,5 0,2 0,6 0,1 0,5 0,7 2,0
Dublin 3% 0,4 0,2 0,3 0,4 62,6 59,8
Gallinarum -- 2,1 4,6 16,2 20,0
Hadar 25% 0,4 0,3 0,5 1,8 1,4 2,3 2,1
Heidelberg 9% 0,5 0,8 0,6 1,8 1,4 1,4 1,1 2,2 4,0
Infantis 14% 0,9 2,8 4,2 6,2 9,5 5,8 9,6 4,8 3,7 8,0
Paratyphi B var Java 7% 0,7 0,7 0,2 1,0 46,9 41,5 56,6 55,9 1,5
Kentucky 33% 1,3 1,1 0,1 0,3 0,2
Livingstone 6% 0,2 0,2 4,4 4,8 1,0 1,7 0,6 1,1 2,9 2,0
London 4% 0,3 0,4 8,6 4,8 0,5 1,1
Mbandaka 17% 0,4 0,2 0,5 0,9 1,1 3,2 3,5 4,2 5,9 1,5
Montevideo 24% 0,4 0,3 0,6 0,4 4,0 2,2 0,6 1,1
Newport 23% 1,3 2,0 0,3 0,4 1,1 0,6
Oranienburg 19% 0,8 0,2 0,1 0,1 0,6 0,7 4,0
Rissen 28% 0,0 0,2 0,8 2,2 0,3 0,1 0,7
Saintpaul 28% 0,7 0,4 0,1 0,4 0,6
Senftenberg 26% 0,4 0,2 0,5 1,3 1,1 1,8 1,7 1,5 1,6 3,7 2,0
Tennessee 8% 0,1 0,4 0,1 0,4 0,6 0,4 2,9
Thompson 9% 0,3 0,2 0,3 1,3 1,2 0,6 0,5 5,9
Virchow 34% 1,5 1,2 0,3 2,3 0,3 2,1 5,1
Weltevreden 25% 0,5 0,3
Goldcoast 2% 0,3 0,2 4,6 2,2
Fluntern -- 0,4 3,7
Panama 6% 1,4 0,9 0,9 0,1 0,1
SI 1,4,5,12:i:- 2% 5,6 7,0 6,4 11,9 0,5 7,6 1,8 0,9 1,5 0,5
(Para)Typhi (A B C) 31% 1,5 2,0
Other -- 10,4 10,3 14,3 24,2 3,0 8,7 8,9 17,9 7,3 11,2 10,3 28,0
Humans Pigs Cattle Poultry Broilers Layers
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As in previous years, S. Enteritidis and S. 
Typhimurium were the most prevalent serovars 
isolated from humans in the Netherlands (Table 
6.1), represented by 33.0% and 32.6% of all 
isolates respectively. Third was again the 
antigenic monophasic variant of S. Typhimurium:  
S. enterica subspecies enterica 1,4,5,12:i:- 
(7.0%), followed by S. Infantis. This Salmonella 
serovar showed a noteworthy increase from 0.9% 
in 2007/2008 to 2.8% in 2009. Both serovars are 
also recovered from animal sources, although 
their relative prevalence varies considerably over 
the years. 
Traditionally, S. Typhimurium has been the most 
detected serovar in pigs. The relative presence 
seems to be decreasing over the years, in 2009 
15.4% of all Salmonella isolates from pigs 
consisted of S. Typhimurium serovars. Other 
commonly found serovars in 2009 were S. 
enterica subspecies enterica 1,4,5,12:i:- (11.9%), 
S. Derby (7.9%), S. Infantis (6.2%), S. 
Bovismorbificans (5.7%), S. Livingstone and S. 
London (both 4.8%).  
 
As in previous years, S. Dublin was by far the 
most prevalent serovar in cattle (59.8%), 
followed by S. Typhimurium (17.4%). 
In poultry, S. Paratyphi B var. Java (S. Java) was 
again the most predominant serovar overall. In 
2009, S. Java was only recovered from samples 
from broiler chickens represented by 55.9% of all 
isolates. In layers, as before, the leading serovar 
in 2009 was S. Enteritidis (28% of all Salmonella 
isolates). The second most prevalent serotype 
among layers in 2009 was S. Gallinarum 
(20.0%), which has been implicated in several 
outbreaks in the Netherlands since the fall of 
2009.  
In 2008 we reported a striking decrease in S. 
Senftenberg prevalence among layers compared 
to previous years (from 24.9% to 1.7%). In 2009, 
its contribution was similar to 2008 (2.0%).  
From 2007 onwards travel contributed up to 34% 
of the cases of human salmonellosis depending 
on the sero/phagetype. A substantial contribution 
was noted for the serovars Virchow (34%), 
Kentucky (33%), and typhoidal Salmonella cases 
(31%). However, several other serovars regularly 
are related to travel abroad. It should be noted 
that the contribution of travel as depicted in Table 
6.1 is only indicative of the true contribution, 
because travel is estimated to be underreported 
by about a factor two. 
 
 
 
Table 6.2. MIC distribution (in %) and resistance percentages (R%) for all Salmonella’s (N = 1901) 
tested for antibiotic susceptibility in 2009 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the 
highest concentration in the range. Values at the lowest concentration tested indicate MIC-values  the lowest concentration in 
the range. The vertical bars indicate the epidemiological cut-off values we used the calculate the resistance percentages, the 
dashed bars indicate clinical breakpoints. 
  
0.015 0.03 0.06 0.13 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 2.1 46.0 27.2 2.9 0.2 0.1 0.1 21.5 21.8 19.9 - 23.7
Cefotaxime 47.3 43.7 6.3 0.9 0.1 1.6 1.7 1.2 - 2.4
Ceftazidime 68.3 27.9 2.1 0.1 0.5 0.1 0.2 0.8 1.6 1.1 - 2.3
Gentamicin 14.5 63.0 19.1 1.8 0.2 0.2 0.3 0.6 0.4 1.6 1.1 - 2.3
Kanamycin 91.8 5.2 0.6 0.1 0.1 2.2 2.9 2.2 - 3.8
Streptomycin 2.4 20.1 20.6 28.0 9.4 3.7 4.7 11.0 19.5 17.7 - 21.3
Tetracycline 3.0 65.0 9.6 0.5 0.2 1.9 3.3 16.4 21.8 20.0 - 23.8
Sulfamethoxazole 51.2 22.3 1.9 0.1 0.1 0.1 0.3 24.0 24.4 22.5 - 26.4
Trimethoprim 86.1 1.3 0.2 0.1 12.5 12.5 11.1 - 14.1
Ciprofloxacin 24.8 59.8 3.2 0.9 6.4 2.4 1.3 0.2 0.1 0.5 0.5 12.3 10.9 - 13.9
Nalidixic acid 82.4 4.7 1.7 0.2 0.3 10.8 11.3 9.9 - 12.8
Chloramphenicol 13.9 73.2 7.0 0.4 0.2 5.3 5.9 4.9 - 7.1
Florfenicol 0.4 41.5 49.5 3.6 0.8 2.3 1.8 5.0 4.1 - 6.1
Colistin 100 0 0 - 0.2
95% CI
Salmonella
N = 1901
MIC (%) distribution mg/L
R%
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Resistance levels 
Table 6.2 presents MIC-distributions and 
resistance percentages of all Salmonella’s tested 
for susceptibility in 2009 (n = 1901). Highest 
levels of resistance were observed for 
sulfamethoxazole, ampicillin, tetracycline, 
streptomycin and to a lesser extend trimethoprim, 
ciprofloxacin, and nalidixic acid. 
Resistance profiles vary considerably among 
serovars as shown in Table 6.3. This table 
presents resistance percentages for the fourteen 
most prevalent serovars isolated in The 
Netherlands in 2009. Highest resistance levels are 
observed in S. Typhimurium, S. Java, the 
monophasic S. enterica subspecies enterica 
1,4,[5],12:i:-, S. Kentucky and S. Virchow. 
In S. Java characteristic findings are high level 
resistance against trimethoprim which is 
characteristic of the clone, in combination with 
acquired resistance against the quinolones and 
third generation cephalosporins cefotaxime and 
ceftazidime.  
 
ESBL’s 
In 2009, 33 cefotaxime reduced susceptible (MIC 
> 0.5 mg/L) ESBL suspected isolates were found. 
The isolates belonged predominantly to the 
serovar S. Java (67%, N = 22). Of 17 of these S. 
Java isolates the origin was reported, all of which 
were recovered from poultry. Other ESBL-
suspected serovars were S. Heidelberg and S. 
Cerro recovered from poultry products; S. 
Enteritidis (Pt 13a), S. Haifa, S. Infantis, S. 
enterica subspecies enterica 1,4,5,12:i:-, and S. 
Typhimurium (ft506) from humans, S. Krefeld 
from spices and S. Virchow from minced meat. 
Eleven of these isolates (33%) were resistant 
against nalidixic acid and also showed reduced 
susceptibility to ciprofloxacin (MIC 0.25 – 2 
mg/L). Resistance against cefotaxime in isolates 
from poultry is increasing at an alarming rate. 
This is associated with transfer of ESBLs 
between E. coli and Salmonella in the GI-tract of 
Dutch poultry (see appendix 1). 
 
Quinolone resistance 
Using the epidemiological cut off value of 0.06 
mg/L, 234 Salmonella isolates (12%) were 
detected that demonstrated a non-wild type 
phenotype for ciprofloxacin. Of these, 24 (1.3%) 
showed MICs larger that the clinical breakpoint 
(1 mg/L). The serovars of these ciprofloxacin 
resistant isolates were predominantly travel 
related S. Kentucky (67%). Other serovars were 
S. Java from poultry (8.3%), S. Cholerasuis 
(8.3%), S. Virchow (4.1%), S. Krefeld (4.1%), S. 
Agona (4.1%) and S. Blockley (4.1%). Since 
2002 annually high-level ciprofloxacin resistant 
S. Kentucky’s were isolated from human patients 
as noted in other EU countries as well. These 
strains are related to travel to North African 
countries and are genetically closely related. 
 
 
Table 6.3. Resistance (%) of the fourteen most prevalent Salmonella serovars isolated in the 
Netherlands in 2009. 
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Ampicillin 7.5 49.2 77.9 61.5 2.7 1.6 2.4 11.4 3.0 0 0 28.0 19.0 20.0
Cefotaxime 0.2 0.3 1.0 22.9 1.4 0 0 0 0 0 0 0 4.8 0
Ceftazidime 0.2 0 1.0 22.9 0 0 0 0 0 0 0 0 4.8 0
Gentamicin 0.2 0 2.9 6.3 1.4 0 0 2.9 0 0 0 40.0 4.8 0
Kanamycin 0.2 0.8 3.8 10.4 5.5 0 0 11.4 0 0 0 4.0 0 5.0
Streptomycin 2.2 38.4 82.7 43.8 11.0 1.6 0 11.4 3.0 3.4 3.6 48.0 19.0 25.0
Tetracycline 4.4 46.3 86.5 21.9 12.3 3.2 2.4 11.4 0 6.9 0 48.0 33.3 25.0
Sulfamethoxazole 1.7 55.3 85.6 62.5 15.1 0 2.4 17.1 0 3.4 7.1 44.0 28.6 35.0
Trimethoprim 0.5 22.5 7.7 93.8 9.6 0 2.4 11.4 3.0 0 3.6 0 28.6 35.0
Ciprofloxacin 13.3 5.6 1.9 51.0 15.1 4.8 4.9 2.9 0 0 0 64.0 66.7 0
Nalidixic acid 12.8 4.8 1.0 46.9 15.1 4.8 4.9 2.9 0 0 0 64.0 61.9 0
Chloramphenicol 0.2 22.2 4.8 6.3 4.1 0 0 2.9 0 0 0 0 0 5.0
Florfenicol 0 21.4 1.0 2.1 2.7 0 2.4 0 0 0 0 0 0 0
Colistin 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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S. Enteritidis 
In the Netherlands, human infections caused by 
S. Enteritidis are predominantly related to the 
consumption of raw shell eggs. In Dutch broilers 
and broiler products the prevalence of S. 
Enteritidis (12.2% and 17.1% respectively) is 
substantially lower than S. Java (55.9% and 
62.2% respectively) as shown in Tables 6.1 and 
6.7. Although S. Enteritidis prevalence varies 
over the years, it is traditionally higher in layers 
than in broiler chickens (Figure 6.1)  
 
The difference in phagetypes isolated from Dutch 
broilers and humans and the moderate resistance 
of strains from human infections compared to the 
lack of resistance in Dutch layers indicates that 
other sources of infection exist amongst them 
travel (Table 6.1) and imported eggs.  
 
In Table 6.4 and Figure 6.2, resistance 
percentages and multidrug resistance for S. 
Enteritidis are specified according to host and 
most prevalent phage types. In 2009, no 
resistance was observed in S. Enteritidis isolated 
from layers, while resistance levels in S. 
Enteritidis recovered from human samples and 
broilers were low. 
Figure 6.1. Salmonella Enteritidis prevalence 
among broilers en layers in the Netherlands. 
Between brackets are the total number of 
poultry isolates sent to the RIVM per year. 
 
 
 
The most commonly recovered phage type in 
2009 was still Pt4 (24.7%), followed by Pt8 
(18.2%) and Pt21 (15.3%). Resistance profiles 
showed some variation among the different phage 
types, most notably with respect to the quinolone 
antibiotics nalidixic acid and ciprofloxacin. 
Highest resistance levels were observed in Pt1 
and Pt14b that are often travel related in humans. 
 
 
 
Table 6.4. Resistance (%) of S. Enteritidis isolated from different sources and phage types 4, 8, 21, 6, 
1, and 14b in 2009. 
 
 
 
Quinolone resistance 
In 2009, 51 ciprofloxacin non wild type 
susceptible strains were isolated from human 
infections, predominantly Pt1 (35%), to a lesser 
extend Pt14b (12%), Pt6a (12%), Pt4 (10%), Pt21 
(8%) and Pt6 (8%). Although Dutch poultry may 
have contributed to the ciprofloxacin non-wild 
type/nalidixic acid resistant isolates found in 
humans, the vast majority of the human 
infections with ciprofloxacin non-wild 
type/nalidixic acid resistant isolates have a non-
domestic source, being either travel related or 
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related to imported contaminated egg-, or poultry 
products.  
In isolates from human infections the resistance 
levels remained stable, while in isolates from 
poultry annual variation is much more apparent 
(Fig. 6.3). After a remarkable peak in resistance 
against the quinolones in 2005 and 2006/2007, 
related to the relative proportion of Pt4 and Pt1, 
levels have decreased to low levels again. It 
should be noted however, because of the small 
numbers of isolates each year, that any 
conclusions on trends must be drawn with great 
care. 
 
 
 
Figure 6.2. Percentages of S. Enteritidis strains fully susceptible, resistant to one to nine different 
antibiotic classes in human and animal sources in the Netherlands in 2009, presented by source (top 
figure) or phage type (lower figure). 
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Figure 6.3. Trends in resistance (%) of S. Enteritidis isolated from 
humans, layers and other poultry sources from 1999 – 2009. 
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S. Typhimurium
As shown in Table 6.1, S. Typhimurium 
represented 32.6% of all human Salmonella 
isolates as characterized by the RIVM in 2009, 
similar to 2007/2008 (31.3%). S. Typhimurium 
was somewhat less frequently found among 
animal isolates, however almost all monophasic 
S. subsp. enterica 4,[5],12:i:- belongs to 
Typhimurium (EFSA opinion) and strongly 
increased. Indeed, both antimicrobial resistance 
profile and animal source corresponds with that 
for S. Typhimurium. In 2009, S. Typhimurium 
represented 15.4% of the porcine (compared to 
22.0% in 2007/2008), and 17.4% of the bovine 
isolates (23.2% in 2007/2008). Note that S. 
Typhimurium was not detected in poultry 
samples in 2009 (compared to 4.0% in 
2007/2008). S. subsp. enterica 4,[5],12:i:- was 
discovered occasionally in broilers. 
Most notable differences in S. Typhimurium 
phage types isolated from human samples are a 
decrease in ft507 (from 9.7% in 2007/2008 to 
8.2% in 2009) and DT104 (or ft506, from 8.3% 
to 5.1%), with the emergence in 2009 of ft353 
(2.0%) and ft90 (1.7%) (Table 6.1). Ft353 was 
also present among 0.4% of porcine and 1.1% of 
bovine isolates, in contrast to ft90 which was not 
detected among animal isolates available in 2009.  
 
 
 
 
Table 6.5. Resistance percentages of S. Typhimurium isolated from different sources and the most 
prevalent phage types in 2009, including monofasic S. subsp. enterica 4,[5],12:i:-. 
 
 
 
 
In 2009 the most predominant phage types of S. 
Typhimurium in the collection of strains received 
from RIVM Bilthoven were: Ft507, Ft506 (≈ 
DT104), Ft353 and Ft90, of which resistance 
profiles are shown in Table 6.5. Also the 
monophasic S. subsp. enterica 4,[5],12:i:- is 
included as this may be regarded as S. 
Typhimurium (EFSA opinion). 
The occurrence of resistance is much more 
common in S. Typhimurium than in S. 
Enteritidis. A typical resistance pattern for S. 
Typhimurium is irrespective of the phage type 
ASTSuCipNalFC. However, as apparent in Table 
6.5, resistance patterns can vary considerably 
according to Typhimurium phage type.  
In 2008, a high prevalence of DT104 was noted, 
concerning a foodborne outbreak of which the 
origin was suspected to be abroad. In 2009, the 
prevalence of this particular phage type decreased 
considerably, although it was still detected 
regularly in human, pig and cattle samples (5.1%, 
3.1%, and 3.3% of all Salmonella isolates 
respectively). 
Multi drug resistance is observed more frequent 
in S. Typhimurium than in S. Enteritidis (Figure 
6.2 and 6.4). Of the S. Typhimurium strains, 48% 
(humans), 65% (cattle), and 64% (pigs) were 
resistant to three or more antibiotic classes (Fig. 
6.4).  
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Figure 6.4. Percentages of S. Typhimurium strains fully susceptible, resistant to one to nine different 
antibiotic classes in human and animal sources in the Netherlands in 2009, presented by source (top 
figure) or phage type, including monofasic S. subsp. enterica 4,[5],12:i:- (lower figure). 
 
 
 
 
Resistance in S. Typhimurium strains from 
humans showed a clear increase in 2008 (Fig. 
6.5), which was attributed to the increased 
incidence of quinolone resistant DT104 in human 
infection in 2008 as a result of a foodborne 
outbreak. As expected, in 2009 resistance 
decreased to levels observed in previous years. 
With regard to animal strains, resistance levels 
vary considerably over the years and 
interpretation should be done with caution 
because of the relatively small number of the 
isolates per year. The trend analysis is further 
affected by the differences in proportion of multi 
drug resistant phage types per category and per 
year. 
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Figure 6.5. Trends in resistance (%) of S. Typhimurium isolated from 
humans and food-animals from 1999 – 2009. 
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S. Paratyphi B var. Java (S. Java) 
As in previous years, in 2009 S. Java was the 
most predominant serovar isolated in broiler 
production. Roughly half of all Salmonella 
strains isolated from poultry were identified as 
such. 
In 2009, eight S. Java strains were isolated from 
human infections. All but two strains were 
trimethoprim susceptible and therefore not 
related to the clone spreading in Dutch poultry 
and probably travel related. From poultry 77 
strains were isolated, all of which harbored the 
phenotype typical for the clone. 
Non-wild type susceptibility to ciprofloxacin 
occurred in 44 (57%) S. Java isolates from 
poultry, two of which (2.6%) showed high level 
resistance to ciprofloxacin (MIC 2 mg/L).  
Resistance to cefotaxime (ESBL-producers) was 
detected in 23% of all isolates and 22% of 
isolates from poultry. This is related to the 
increase in ESBLs in commensal E. coli from 
broilers since 2003, by horizontal transfer of 
plasmid mediated beta-lactamases. Third-
generation cephalosporins are not used in broiler 
production, but the use of ceftiofur in 
combination with Marek vaccine or with in ovo 
vaccination is a common off-label use procedure 
in the poultry reproduction and breeding sectors. 
It is likely that this has contributed to selection 
and vertical transmission of ESBLs in the poultry 
production pyramids and was recently described 
to occur in Canada (Dutil et al., Emerging 
Infectious Diseases 2010 Jan;16(1):48-54).  
 
In 2009, also in raw poultry meats S. Java was 
still by far the most prevalent serovar isolated 
(Table 6.7). Resistance levels for the quinolones 
and cephalosporins are similar as observed in 
isolates from broilers (Table 6.6, Figure 6.7). 
 
 
 
Figure 6.6. Trends in resistance (%) of S. Paratyphi B var. Java isolated from poultry from 1999 – 
2009 and humans (Separate data on the right indicate all human S. Java isolates from 1999 – 2009). 
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Salmonella in raw meats at retail 
Resistance trends are presented for poultry meat 
only, because in beef and pork the numbers of 
isolates examined are too small to provide an 
accurate estimate (Fig. 6.8). The variable 
contribution of S. Java to the annual resistance 
percentages over all serotypes hampers the 
interpretation of the observed trend in the 
resistance. Resistance against cefotaxime and 
ceftazidime  occurred frequently in poultry meat 
isolates. 
 
 
 
Table 6.6. Resistance (%) of Salmonella enterica isolated from raw meats from poultry, 
and other raw meat sources in 2009. 
 
 
 
Figure 6.7. Trends in resistance (%) of Salmonella enterica subspecies enterica 
isolated from poultry meats in the Netherlands from 2001 – 2009.  
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Table 6.7. Distribution of Salmonella serovars, in poultry meat at retail (Surveillance data of the New 
Food and Consumer Product Safety Authority (nVWA) from 1997 – 2009 
 
 
 
 
Distribution of Salmonella serovars, in poultry 
meat. 
Table 6.7 presents the contamination rates of 
Salmonella in poultry meat products over the 
years. The contamination decreased from 29.1% 
in 1997 to a stable rate of approximately 8% in 
the last few years.  
The distribution of Salmonella serovars in 
poultry meat correspond with those from fecal 
samples (Tables 6.1 and 6.7), the contamination 
rate of S. Java continues to predominate while for 
the first year, S. Typhimurium was not identified. 
Also for S. Enteritidis, after a decrease to low 
levels in the previous years the contamination 
rate in meat shows a remarkable increase, like in 
live poultry (Table 6.1).  
 
Salmonella in animal feeds, turkeys, horses, 
ducks, pigeon and reptiles 
Table 6.8 presents the most prevalent serovars 
found in animal feeds from 2001 – 2009 per 
single and or compound feed type. Additionally, 
R% of Salmonella strains isolated from incidental 
animal sources are presented. The serotypes 
Senftenberg, Agona, Mbandaka, Lexington and 
Rissen are again most frequently isolated from 
animal feeds. Resistance in these serovars is 
uncommon compared to isolates from animals or 
human sources except tetracycline resistance. 
Resistance against cefotaxime is incidentally 
present in isolates from soy and compound feeds. 
In Salmonella isolates from turkeys and horses, 
more resistance was observed than in strains from 
ducks, pigeons, or reptiles. Nalidixic acid and 
ciprofloxacin resistance was highest in turkeys 
and ducks, animals with a substantial 
consumption of quinolones (only 
fluoroquinolones are licensed for use in Turkeys). 
Cephalosporin resistance was also observed in 
isolates from turkeys. 
 
  
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
N samples 1,314 1,077 859 1,454 1,578 1,600 1,510 1,482 1,474 1,539 1,403 1,505 1,042
% Salmonella  spp. 29.1 20.2 17.6 21 16.3 13.4 11.3 7.4 9.4 8.4 8.1 8.1 7.9
(organic) 3.4 2.1 1.9 4
Paratyphi B Java 15.0 11.4 13.9 33.1 43.2 53.5 45.6 58.2 46.8 38.5 59.6 76.2 62.2
Enteritidis 20.2 12.8 26 6.6 8.2 2.3 8.8 5.5 7.2 6.6 2.0 1,6 17.1
Hadar 10.1 6.1 5 3.3 4.2 0.9 1.8 1.4 5.7 1,0 2.5 2.4
Indiana 6.1 8.3 9.3 10.2 11.6 6.5 6.4 1.8 2.2 4.1 6.1 0.8 2.4
Infantis 9.2 5.0 3.6 6.6 7.0 7.9 11.7 11.5 13.9 13.1 4.9 9.8
Virchow 4.6 2.8 3 10.2 3.5 5.6 5.8 4.5 8.6 11.5 4 1.6
Typhimurium 7.8 3.6 1.3 0.1 7.4 7.4 5.8 3.6 5.0 1.6
  (DT104) 0 1.8 0.7 0.1 7.0 2.8 5.3 0 2.2 0
Corvallis 4.3 1.6
other 27.0 53.6 39.7 30.0 22.3 23.3 19.9 26.4 13.0 16.5 13.2 11.6 6.1
1.0 0.8 0
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Table 6.8. The most prevalent serovars isolated from animal feed and resistance (R%) of isolates of 
Salmonella enterica per single and or compound feed type in 2001 – 2009. Additionally, R% of 
Salmonella strains isolated from incidental animal sources over 2001 – 2009 are presented. 
 
 
 
 
 
Salmonella in other European countries7 
Salmonella isolates from humans 
Overall, S. Enteritidis (57.8%) and S. Typhimurium 
(25.7%) were the two most commonly reported 
Salmonella serovars of all reported confirmed human 
cases in 2009 in reporting member states. Compared 
to European figures their relative prevalence differed 
somewhat in the Dutch situation, in which S. 
Enteritidis and S. Typhimurium represented 33.0% 
and 32.6% of all human cases respectively.  
Like in the Netherlands, also in some other European 
countries S. Typhimurium DT104 appears to be 
declining and monophasic S. Typhimurium strains, in 
particular 4,5,12:i:- is now emerging as a dominant 
Salmonella serovar. 
 
Resistance levels showed considerable variation 
among different member states, and resistance 
percentages of Dutch Salmonella isolates showed no 
exceptional differences. The relative high 
ciprofloxacin resistance reported in S. Typhimurium 
and S. Enteritidis in the Netherlands may be the result 
of frequent usage of quinolones in broiler chickens. 
Similar to the Netherlands, cefotaxime resistance was 
overall low in reporting member states. 
 
Salmonella isolates from animals and food 
In S. Enteritidis from poultry, the overall occurrence 
of ciprofloxacin resistance was 17 %, with varying 
levels from 0.4 % to 65% amongst different member 
states. The levels reported by the Netherlands were 
modest (6%) compared to the high levels reported by 
                                                     
7 The Community Summary Report. Antimicrobial resistance in 
zoonotic and indicator bacteria from humans, animals and food 
in the European Union in 2009. 
Spain, Portugal and Poland (65%, 48% and 29% 
respectively). Resistance to cefotaxime in S. 
Enteritidis was 0.2% on average in the reporting 
member states including the Netherlands.  
Resistance in S. Typhimurium from pigs and cattle 
ranged considerably among the different countries. 
The occurrence of resistance in the Netherlands was 
not exceptional compared to other European 
countries. The resistance levels to the clinically 
important fluoroquinolones and third-generation 
cephalosporins were comparable to the overall 
occurrence of resistance in all reporting member 
states.
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Agona 210 cefotaxime 0 0 0.2 0 0 0.6 0 0.2 1.9 0 0 0 0
Mbandaka 190 cefuroxime 0 0 0 0 0 0 -- 0 0 0 -- 0 0
Lexington 173 ceftazidime 0 0 0.2 0 0 0 0 0 2.6 0 0 0 --
Rissen 138 imipenem 0 0 0 0 0 0 -- 0 0 0 -- 0 0
Cubana 131 gentamicin 0 0 0 0 0.5 0 0.4 0.1 12.5 0 0 0 0
Livingstone 107 neomycin 0 1.4 0.5 0 1.7 0 7.8 0 14.9 0 0 0 0
Tennessee 85 doxy/tetracycline 0 2.8 0.9 0.3 1.7 5.6 2.7 1.3 42.3 19.1 5 6.7 2.9
Anatum 84 cotrimoxazol 0 0 0.5 0 0.8 0 -- 0.4 0 33.3 -- 0 0
Havana 68 sulfamethoxazole 0 0 0.5 1.9 1.8 6 1.8 1.3 35.2 13.8 0 9.1 --
Kentucky 59 trimethoprim 0 1.4 0.5 0.8 0.2 3.7 1.3 0.7 11.5 19.1 5 0 0
Oranienburg 45 ciprofloxacin 1.7 1.4 0.4 0 1.2 3.7 2.2 0.6 47.1 2.1 15 0 0
Minnesota 39 naladixic acid 0 1.4 0.3 0 1 3.1 2.2 0.4 40.4 2.1 10 0 0
Infantis 38 chloramphenicol 0 1.4 0.7 0.8 1.7 2.5 0.9 1.1 5.8 17 5 11.1 1.4
Montevideo 38 florfenicol 0 0 0.5 0.8 0.7 0 0.4 0.5 3.8 6.4 0 11.1 1.4
Cerro 34 streptomycin -- -- 8.3 4 11.5 3.4 8.9 5.6 -- -- -- -- --
Yoruba 31 kanamycine -- -- 9.2 12 12.8 3.4 9.8 11.1 -- -- -- -- --
17 main 
serotypes
1739 (82%)
all serotypes 2117
Animal feed (or ground substance) Animals
%  resistant isolates 2001-2009 %  resistent 2001-2009
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Campylobacter spp. 
 
 
In Table 6.9 the MIC-distributions and resistance 
percentages are summarized for all Campylobacter 
jejuni and Campylobacter coli strains isolated from 
broilers, pigs, cattle and veal calves in 2009. Table 
6.10 shows the more detailed resistance profiles of C. 
jejuni and C. coli according to the different sources 
(meat as well as from fecal samples from different 
animal species). Figure 6.7 presents trends over the 
last decade in resistance of C. jejuni and C. coli 
recovered from the different sampling categories.  
National surveillance data from 2002 onwards for 
Campylobacter spp. isolated from humans are shown 
in Figure 6.8, and Tables 6.11 and 6.12. Finally, 
isolation rates of Campylobacter in poultry products 
at retail from 1998-2009 are depicted in Figure 6.9. 
 
 
Highlights 
 
In C. jejuni in animal species highest levels of resistance were detected against tetracycline (45.4%), ampicillin 
(40.2%) and the quinolones (37.1% and 38.1% for ciprofloxacin and nalidixic acid, respectively). Resistance against 
tetracyclines varied among different animal species, with very high levels in veal calves (70% for C. jejuni and 96.8% 
for C. coli). In C. jejuni from human origin, highest level of resistance was noted against fluoroquinolones (53.2%), 
followed by tetracycline (26.5%). In 2009, 1.3% of the isolates were resistant against erythromycin. 
Resistance to macrolide antibiotics (erythromycin, clarithromycin and tulathromycin) was more commonly observed 
in C. coli (17.7%) than in C. jejuni (2.1%). Notable is the high level of resistance in C. coli from veal calves, with 
25.8% of the isolates resistant against erythromycin, clarithromycin and tulathromycin. 
In 2009 a decrease in quinolone resistance was observed in Campylobacter from broilers and poultry meat, after a 
steady increase in previous years. Among C. coli from pigs, the low level of resistance against the quinolones (5.1%)  
is remarkable and consistent with previous years. 
 
 
 
 
In 2009, among C. jejuni highest resistance levels 
were observed for ampicillin (40.2%), tetracycline 
(45.5%) and the quinolones nalidixic acid (38.1%) 
and ciprofloxacin (37.1%). However, in general, 
resistance was more frequent in C. coli, where 
additional resistance was commonly observed against 
streptomycin (in 70.8% of the isolates), and 
sulfamethoxazole (50.8%). Also with regard to 
macrolide drugs (erythromycin, tulathromycin ad 
clarithromycin) resistance was more frequently 
present in C. coli (17.7%) compared to C. jejuni 
(2.1%). 
 
Quinolones 
For the first time in years, 2009 saw a decrease in 
resistance against nalidixic acid and ciprofloxacin in 
C. jejuni isolated from poultry. Ciprofloxacin 
resistance in C. jejuni from broilers and poultry meat 
was observed in 42.6% and 48.1% of the isolates 
respectively (Table 6.10.). In contrast, ciprofloxacin 
resistance among C. jejuni recovered from humans 
continued to increase from 50.5% in 2008 to 53.1% in 
2009 as shown in Figure 6.8. and Table 6.11. 
Also in C. coli from broiler chickens, the 
ciprofloxacin resistance rate was lower in 2009 
compared to the previous year (from 86.7% to 
62.5%). It should be noted though that the number of 
strains available for testing were limited. Resistance in 
C. coli from pigs and veal calves for nalidixic acid 
and ciprofloxacin remained stable at 5.1% and 74.2%, 
respectively in 2009.  
 
Macrolides 
With regard to the macrolide drugs, resistance among 
C. jejuni is still rare in all animal species. In 2009, 
resistance rates for most sample categories were 
slightly lower than in the previous year. For instance 
erythromycin in C. jejuni from broiler chickens 
decreased from 5.6% in 2008 to 1.6% in 2009, while 
rates in C. jejuni from poultry meat were 4.2% in 
2008 and 1.3% in 2009. However, these changes are 
not statistically significant. 
Macrolide resistance is more frequently present in C. 
coli compared to C. jejuni with similar resistance rates 
for all three macrolide agents included in the test 
panel. In 2009, 17.7% of C. coli isolates were resistant 
against erythromycin, tulathromycin as well as against 
clarithromycin and 2.1% of C. jejuni isolates (Table 
6.9). Highest level resistance was observed in C. coli 
recovered from veal calves and pigs, probably 
reflecting the use of macrolides in the pig and veal 
calf husbandry in the Netherlands (Table 6.10.). 
In Campylobacter spp. isolated from humans 
resistance against erythromycin remained stable at a 
low frequency (Figure 6.8 and Table 6.11). 
 
  
Maran 2009 
 
 
 40 
 
Table 6.9. MIC distribution (in %) for all Campylobacter jejuni (N = 97, of which 61 from broilers, 11 from 
dairy cows, 5 from pigs and 20 from veal calves) and Campylobacter coli (N = 130, of which 79 from pigs, 16 
from broilers, 4 from dairy cows and 31 from veal calves) 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the highest 
concentration in the range. Values at the lowest concentration tested indicate MIC-values  the lowest concentration in the range. Vertical 
bars indicate the epidemiological cut-off values, used as breakpoints. 
 
 
 
Tetracycline 
In Campylobacter spp. isolated from humans 
resistance against tetracyclines varied around 20% 
(Figure 6.8 and Table 6.11), although some 
discrepancy was seen in data obtained from individual 
regional Public Health Laboratories in comparison to 
the national surveillance data (Figure 6.8), which may 
be the result of different methodologies and 
interpretive criteria used. For C. coli and C. jejuni 
from animal sources, resistance levels against 
tetracycline were much higher (up to 96.8% in C. coli 
from veal calves) as shown in Table 6.10. 
 
Ampicillin 
Compared to 2008, resistance against ampicillin 
among Campylobacter increased significantly (from 
27.8% to 40.2% for C. jejuni and from 17.3% to 
28.5% in C. coli). The increase in ampicillin 
resistance was apparent in all animal species, as well 
as in samples from meat. The most striking increase 
was seen in C. jejuni and C. coli from cattle. For 
instance ampicillin resistance increased from 0% in 
dairy cows in 2008 to 27.3% in 2009. Also ampicillin 
resistance in C. coli from veal calves showed a 
statistical significant increase, from 13.5% in 2008 
(n=52) to 35.5% (n=31) in 2009. For veal calves an 
increase was noted in C. jejuni from 9.1% in 2008 to 
25.0% in 2009. 
Ampicillin resistance in C. jejuni and C. coli varies 
considerably in time. In 2008, for C. coli from pigs a 
large increase in resistance was reported against 
ampicillin, while resistance in C. jejuni from broilers 
showed a marked decrease. However for both 
combinations, resistance rates in 2009 were again 
comparable to those seen in previous years (Figure 
6.7.). 
  
C. jejuni
(N = 97) 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 R% 95% CI
Ampicillin 1.0 2.1 26.8 29.9 16.5 1.0 22.7 40.2 30.9-50.5
Gentamicin 79.4 17.5 3.1 0 0-0.04
Neomy cin 90.7 7.2 1.0 1.0 2.1 0-5.2
Streptomy cin 96.9 1.0 1.0 1.0 2.1 0-5.2
Tetracy cline 37.1 1.0 16.5 4.1 1.0 1.0 15.5 23.7 45.4 35.1-55.7
Sulfamethox azole 9.3 22.7 26.8 28.9 9.3 2.1 1.0 3.1 0-7.2
Ciproflox acin 40.2 20.6 1.0 1.0 1.0 19.6 10.3 6.2 37.1 27.8-46.4
Nalidix ic acid 5.2 34.0 21.6 1.0 1.0 1.0 21.6 14.4 38.1 28.9-47.4
Ery thromy cin 25.8 48.5 19.6 4.1 2.1 2.1 0-5.2
Clarithromy cin 19.6 39.2 32.0 5.2 2.1 2.1 2.1 0-5.2
Tulathromy cin 50.5 41.2 5.2 1.0 2.1 2.1 0-5.2
Chloramphenicol 42.3 37.1 17.5 3.1 0 0-0.04
C. coli
(N = 130) 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 R% 95% CI
Ampicillin 0.8 3.1 9.2 26.9 31.5 14.6 13.8 28.5 20.8-36.2
Gentamicin 23.8 64.6 10.8 0.8 0.8 0-2.3
Neomy cin 56.2 30.8 0.8 0.8 3.8 0.8 1.5 5.4 12.3 6.9-18.5
Streptomy cin 26.2 3.1 0.8 20.8 30.8 3.1 0.8 14.6 70.8 63.1-78.5
Tetracy cline 6.2 2.3 2.3 8.5 0.8 1.5 6.9 71.5 89.2 83.8-94.6
Sulfamethox azole 7.7 14.6 16.9 9.2 0.8 16.9 20.8 13.1 50.8 42.3-59.2
Ciproflox acin 41.5 29.2 0.8 0.8 7.7 17.7 2.3 28.5 20.8-36.2
Nalidix ic acid 15.4 46.9 5.4 3.8 12.3 16.2 28.5 20.8-36.2
Ery thromy cin 7.7 16.9 31.5 19.2 6.9 17.7 17.7 11.5-24.6
Clarithromy cin 7.7 13.8 33.1 17.7 9.2 0.8 0.8 16.9 17.7 11.5-24.6
Tulathromy cin 36.2 33.1 10.8 1.5 0.8 2.3 15.4 17.7 11.5-24.6
Chloramphenicol 3.1 30.8 49.2 16.2 0.8 1 0-2.3
MIC (%) distribution mg/L
MIC (%) distribution mg/L
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Table 6.10. Resistance percentages of Campylobacter jejuni and Campylobacter coli isolated from raw meat 
from poultry and from faecal samples of broilers, veal calves, dairy cows (only C. jejuni) and pigs (only C. coli) 
in 2009. 
 
 
 
 
For most antimicrobial drugs, resistance rates varied 
depending on the animal host and Campylobacter 
subspecies. Most striking differences were found 
among C. coli with regard to aminoglycosides, 
macrolides and quinolones (Table 6.10.). Resistance 
data in various animal species reflect the application 
of antibiotics of choice in different animal sectors 
(Table 6.10). Quinolone resistance is most common 
among C. coli from broiler chickens (62.5%) and veal 
calves (74.2%), but low in C. coli from pigs (5.1%), 
reflecting the use of this class of antibiotics. 
 
In Campylobacter from humans resistance against 
ciprofloxacin shows a constant tendency to increase, 
while resistance against tetracycline and erythromycin 
remain stable. Possible discrepancies in resistances 
levels observed in humans versus animal isolates may 
be explained by the fact that mostly disk diffusion is 
applied at the regional Public Health Laboratories, 
which is not standardized and for which no accepted 
interpretive criteria are defined 
 
For Campylobacter from poultry, resistance profiles 
for isolates recovered from faecal samples as well as 
from meat samples are shown (Table 6.10 and Figure 
6.7.). No statistically significant differences were 
found for resistance rates in Campylobacter isolates 
from the different sources. 
 
. 
 
poultry products broilers veal calves dairy cows poultry products broilers veal calves pigs
N 233 61 20 11 64 16 31 79
Ampicillin 51.9 45.9 25.0 27.3 25.0 31.3 35.5 24.1
Gentamicin 0.4 0 0 0 0 0 3.2 0
Neomycin 3.4 1.6 5.0 0 10.9 0 32.3 7.6
Streptomycin 2.6 1.6 5.0 0 7.8 25.0 58.1 86.1
Tetracycline 53.2 44.3 70.0 27.3 68.8 81.3 96.8 89.9
Sulfamethoxazole 8.6 4.9 0 0 20.3 43.8 22.6 64.6
Ciprofloxacin 48.1 42.6 30.0 27.3 57.8 62.5 74.2 5.1
Nalidixic acid 49.8 44.3 30.0 27 59.4 62.5 74.2 5.1
Erythromycin 1.3 1.6 5.0 0 20.3 6.3 25.8 17.7
Tulathromycin 1.3 1.6 5.0 0 18.8 6.3 25.8 17.7
Clarithromycin 1.3 1.6 5.0 0 17.2 6.3 25.8 17.7
Chloramphenicol 0.4 0 0 0 0 0 3.2 0
C. jejuni C. coli
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Figure 6.7. Trends in resistance (%) of Campylobacter jejuni (isolated from broilers) and Campylobacter coli 
(from broilers and slaughter pigs) from 2000 - 2009 in the Netherlands. 
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Figure 6.8. Trends in resistance (%) of Campylobacter spp. isolated from 
humans between 1992 and 2009 at the regional Public Health Laboratories 
(PHLS) of Arnhem and Heerlen covering 990.000 inhabitants (400-700 isolates 
per year). The continuous line represents national surveillance data from 2002 
onwards; the average number of strains tested per year was approximately 
2400, ranging from 1900 – 2900.  
 
 
 
 
Table 6.11. Percentage Campylobacter jejuni and Campylobacter coli 
isolates from humans resistant against fluoroquinolones, tetracycline 
and erythromycin from 2002 to 2009. 
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Table 6.12. Domestically acquired and travel related resistance in C. jejuni and C. coli isolated from humans 
from 2002 - 2009 from all 16 PHLS covering >50% of the Dutch population. 
 
 
 
 
In analogy to previous years, in travel-related 
Campylobacter infections fluoroquinolone resistance 
occurred more frequently than in domestically 
acquired infections as shown in Table 6.12. For 
tetracycline and erythromycin this difference was 
observed for C. jejuni only. 
 
In the surveillance program carried out by the Dutch 
new Food and Consumer Product Safety Authority 
(nVWA), meat from different animal species (sample 
size 1100-1500 per year) are tested for the presence of 
zoonotic food pathogens. Isolation rate data for 
Campylobacter spp. are shown in Figure 6.9. After a 
decline in 2006 and 2007, contamination levels in 
poultry products are again comparable to the levels in 
previous years. The levels in organic poultry are 
slightly higher than in conventionally raised animals. 
 
 
 
Figure 6.9. Isolation rates of Campylobacter in 
poultry meat at retail, from 1998-2009. 
 
 
 
 
Campylobacter in other European countries8 
Antimicrobial resistance levels in C. jejuni from 
humans in the Netherlands were similar (erythromycin 
and ciprofloxacin) or slightly lower (tetracycline) than 
the mean of values reported from other European 
countries. 
Also for Campylobacter spp. from animals and meat, 
levels in the Netherlands were generally comparable 
                                                     
8The Community Summary Report. Antimicrobial resistance in 
zoonotic and indicator bacteria from humans, animals and food 
in the European Union in 2009 
to the mean of values reported from other European 
countries. However, the resistance levels in individual 
countries varied substantially. It should be noted that 
the guidelines used for the methodology and 
interpretation of the antimicrobial susceptibility 
testing for Campylobacter may still differ between 
countries, which complicates the interpretation and 
comparison of results between countries. 
N R% N R% N R% N R% N R% N R% N R% N R%
Fluoroquinolone 6792 32.7 386 36.3 600 53.5 56 50 7091 48.2 573 48.2 331 61.9 31 54.8
Tetracycline 5028 18.5 353 22.7 425 27.1 49 20.4 4548 18.6 437 31.4 112 27.7 18 33.3
Erythromycin 5735 1.2 372 3 511 1.6 52 0 5822 2 492 5.5 256 3.9 24 4.2
2007-2009
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C. jejuni C. coliC. jejuni C. coli C. jejuni C. coli C. jejuni C. coli
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Shiga-toxin producing E. coli O157 (STEC) 
 
 
 
Highlights 
 
Among human isolates of STEC E. coli O157 resistance levels have been traditionally low. The increase noted in 
2008 was absent in 2009. Highest level of resistance among human isolates was noted for streptomycin and 
sulfamethoxazole (in 9.5% of the isolates). 
As expected, resistance in isolates from cattle was more commonly present. Resistance against streptomycin and 
sulfamethoxazole was seen in 32% and 20% of bovine isolates respectively. Resistance was further noted against 
tetracycline (17.3%). 
Based on MIC profiles, no extended spectrum beta-lactamases (ESBL) suspect phenotypes were present as all human 
and animal isolates were susceptible to cefotaxime and ceftazidime.  
 
 
 
 
In 2009, 138 Shiga-toxin producing E. coli O157 
(STEC) isolates were tested for susceptibility. Isolates 
were obtained from human patients (N = 63) and from 
cattle (N = 75). MIC results are shown in Table 6.14. 
Of the bovine isolates, 53 were recovered from veal 
calves, and 22 from dairy cattle. No statistical 
significant differences in resistance profiles were 
noticed between both sample sources (data not 
shown). 
 
Traditionally, resistance in E. coli O157 from human 
specimens is very low, while in cattle strains 
resistance occurs more commonly. In 2009, highest 
levels of resistance in bovine strains were seen against 
streptomycin (32%) and sulfamethoxazole (20%).  
As in previous years, no resistance was detected in 
human or cattle strains against third generation 
cephalosporins (cefotaxime or ceftazidime) which is 
considered to be an indication for the presence of 
extended spectrum beta-lactamases (ESBLs). 
 
Trends in resistance 
Although annual resistance rates vary to some extent, 
resistance in animal isolates show a tendency to 
increase over the last few years (Figure 6.9). Also in 
human isolates, an increase was noted in resistance 
profiles of 2008. However, in 2009 resistance levels 
were again fairly low. Highest rates of resistance in 
strains isolated from human samples were observed 
for sulfamethoxazole and streptomycin (both 9.5%). 
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Table 6.14. MIC distribution (in %) for STEC E. coli O157 isolated in the Netherlands from human (N=63) and 
cattle faeces (N=75) in 2009. 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the highest 
concentration in the range. Values at the lowest concentration tested indicate MIC-values  the lowest concentration in the range. Vertical 
bars indicate the cut-off values used as breakpoints. Dashed bars indicate the clinical breakpoints. 
Humans
N = 63 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 3.2 92.1 1.6 3.2 3.2 0-7.9
Cefotaxime 93.7 6.3 0 0-0.06
Ceftazidime 100.0 0 0-0.06
Gentamicin 3.2 74.6 15.9 4.8 1.6 1.6 0-4.8
Kanamycin 95.2 4.8 0 0-0.06
Streptomycin 54.0 34.9 1.6 3.2 6.3 9.5 3.2-17.5
Tetracycline 47.6 47.6 4.8 4.8 0-11.1
Sulfamethoxazole 90.5 9.5 9.5 3.2-17.5
Trimethoprim 98.4 1.6 1.6 0-4.8
Ciprofloxacin 68.3 31.7 0 0-0.06
Nalidixic acid 98.4 1.6 0 0-0.06
Chloramphenicol 3.2 69.8 25.4 1.6 1.6 0-4.8
Florfenicol 6.3 77.8 15.9 0 0-0.06
Colistin 98.4 1.6 0 0-0.06
Cattle
N = 75 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 16.0 70.7 9.3 4.0 4.0 0-9.3
Cefotaxime 94.7 1.3 4.0 0 0-0.05
Ceftazidime 98.7 1.3 0 0-0.05
Gentamicin 20.0 64.0 12.0 4.0 4.0 0-9.3
Kanamycin 90.7 2.7 6.7 6.7 1.3-13.3
Streptomycin 50.7 16.0 1.3 1.3 20.0 4.0 6.7 32.0 21.3-42.7
Tetracycline 18.7 64.0 1.3 2.7 13.3 17.3 9.3-26.7
Sulfamethoxazole 20.0 30.7 29.3 20.0 20.0 12-29.3
Trimethoprim 90.7 1.3 8.0 8.0 2.7-14.7
Ciprofloxacin 50.7 45.3 2.7 1.3 1.3 0-4
Nalidixic acid 94.7 5.3 0 0-0.05
Chloramphenicol 84.0 8.0 8.0 8.0 2.7-14.7
Florfenicol 25.3 70.7 4.0 4.0 0-9.3
Colistin 100.0 0 0-0.05
MIC (%) distribution mg/L
R% 95% CI
MIC (%) distribution mg/L
R% 95% CI
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Figure 6.9. Trends in resistance percentages of E. coli O157 (STEC) isolated in The Netherlands from 1998 – 
2009. 
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Figure 6.10. Percentages of STEC E. coli O157 strains fully susceptible, resistant to one 
to a maximum of nine antimicrobial classes from human and cattle specimens in 2009. 
 
 
 
 
Multidrug resistance 
Information on multiple drug resistance is shown in 
Figure 6.10. Concerning human isolates, three out of 
63 isolates (5%) were resistant against two or more 
classes of antibiotics. All three isolates were resistant 
against tetracyclines and sulfamethoxazole, with 
additional resistance against ampicillin and 
trimethoprim (one isolate) or ampicillin and 
chloramphenicol (one isolate). With respect to isolates 
from cattle, 13 out of 75 isolates (17%) were resistant 
against two or more classes of antibiotics. Resistance 
profiles were similar to those from human origin, i.e. 
all “multidrug resistant” isolates were resistant against 
tetracyclines and sulfamethoxazole, with additional 
resistance in six isolates (8%) against trimethoprim, 
chloramphenicol, aminoglycosides and/or ampicillin. 
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7. Commensal indicator organisms 
 
 
 
This chapter describes the susceptibility profiles of 
commensal micro-organisms of the gastro-intestinal 
(GI) tract. The level of antimicrobial resistance in 
bacteria inhabiting the intestinal tract directly reflects 
the selection pressure as a result of the use of 
antibiotics in animals, especially over time. For this 
purpose,  E. coli and Enterococcus species (E. faecium 
and E. faecalis) are included as indicator organisms 
for the Gram-negative and the Gram-positive flora, 
respectively.  
 
Isolation of bacteria from the intestine of randomly 
picked animals (broiler chickens and pigs) at slaughter 
aims to detect the development of resistance at the 
bacterial population level in food animals.  
From 2005 onwards, resistance in isolates from both 
dairy cattle and veal calves have been included in the 
monitoring, using the same samples that were taken at 
farms to determine the prevalence of Salmonella, E. 
coli O157 and Campylobacter.  
 
It should be noted however, that the sampling strategy 
implies that this method is inherently insensitive for 
detecting resistance as only one randomly selected 
isolate is tested from a single sample taken from one 
animal per epidemiological unit (herd or flock). The 
total set of selected isolates is intended to represent the 
E. coli, or Enterococcus species population of each 
animal species of the entire country. One per cent 
resistance in e.g. E. coli indicates that in all animals 
1% of the E. coli bacteria are resistant. Because each 
animal harbours about 106 cfu/g faeces E. coli in its 
gut, 1% would be approximately 104 cfu/g faeces. 
This means that the absence of resistance in these 
datasets does not exclude the possibility that resistance 
is present in small numbers in each animal. 
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Escherichia coli 
This chapter presents information on resistance in 
Escherichia coli from food-producing animals in the 
Netherlands as indicator organisms for the occurrence 
and trends in resistance in Gram-negative bacteria 
present in the GI-tract of food-producing animals. 
Isolates were selected from chickens, pigs, and cattle. 
In 2009, for 1317 E. coli strains MIC values have been 
determined. In addition to susceptibility profiles of 
897 isolates from live animals, data on 420 E. coli 
isolated from raw meat products are presented. 
In Table 7.1 MIC distributions are summarized for E. 
coli strains isolated from fecal samples in 2009. Figure 
7.1 presents information on trends in resistance levels 
over time according to host animal species. Trends in 
multidrug resistance are depicted in Figure 7.2.  
Data for 2009 on E. coli isolated from different meat 
products are presented in Table 7.2. as well as in 
Figure 7.3 (showing trends in resistance percentages 
from 2002 to 2009). 
 
 
Highlights 
 
For most antibiotic classes the trend for increasing resistance continues in 2009. Notably resistance against beta-lactam 
antibiotics is disturbing. Resistance against 3rd and 4th generation of cephalosporins, indicative of ESBL producing E. 
coli, has further increased compared to 2008. Cefotaxime resistance was detected in all animal host species, ranging 
from 1.5% in dairy cattle to 17.9% in broiler chickens.  
The increase of resistance in commensal E. coli isolated from dairy cows noted in the last five years was again 
apparent in 2009.  
 
 
 
Table 7.1 presents the MIC distributions and 
resistance percentages for E. coli strains isolated from 
farm animals in 2009 specified for broiler chickens, 
slaughter pigs, veal calves and dairy cows. Although 
resistance rates vary among the different animal 
species, universally highest resistance is seen against 
ampicillin, tetracycline, streptomycin, trimethoprim 
and sulfamethoxazole. These include the drug classes 
that are most frequently used in veterinary medicine. 
In addition, reduced susceptibility to quinolones is 
commonly encountered in E. coli isolated from broiler 
chickens; 57.4% of all isolates that were tested 
showed non-wild type susceptibility9 to nalidixic acid 
and ciprofloxacin. In 2009 high level resistance (MIC 
>1 mg/L) against ciprofloxacin in broiler chickens 
was detected in 5.4%, compared to 6.3% of the 
isolates in 2008. 
 
Poultry 
In the last decade the resistance percentages of E. coli 
from broilers show a tendency to increase for most 
antibiotics included in the test panel. For beta-lactam 
antibiotics this increase was substantial. In 2009 as 
much as 73.2% of commensal E. coli from broilers 
were resistant against ampicillin, while 17.9% of the 
E. coli strains were resistant against cefotaxime, 
indicative of ESBL production (Table 7.1). In 
comparison, in 1998 resistance rates against ampicillin 
and cefotaxime were 38.9% and 2.6% respectively.  
In broilers tetracycline resistance seems to be fairly 
stable over the years, varying from 52.6% (2006) to 
66.7% (2004). In 2009, tetracycline resistance was 
                                                     
9 a micro-organism is defined as wild type (WT) for a species by 
the absence of acquired and mutational resistance mechanisms to 
the drug in question. Wild type micro-organisms may or may not 
respond clinically to antimicrobial treatment 
(http://www.eucast.org). 
observed in 61.9% of the E. coli isolated from broiler 
chickens. Also resistance against trimethoprim and 
sulfamethoxazole was widespread in commensal E. 
coli from broiler chickens (62.2% and 71.5% 
respectively). 
With respect to aminoglycoside antibiotics, highest 
resistance rates were seen against streptomycin 
(67.4%), representing an increase since 2007 (51.2%) 
and 2006 (60.0%) when streptomycin was first 
included in the selection of antibiotics tested. 
Moreover, the majority of resistant E. coli showed 
high level resistance against streptomycin as reflected 
in MIC ≥256 mg/l. Resistance against kanamycin 
(17.2%) and gentamicin (8.6%) was less commonly 
seen. 
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Table 7.1. MIC distributions (in %) for E. coli isolated as indicator organism from intestines of broiler 
chickens (N=291), slaughter pigs (N=296), veal calves (N=171) and dairy cattle (N=136) in The 
Netherlands in 2009. 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the 
highest concentration in the range. Values at the lowest concentration tested indicate MIC-values  the lowest concentration in the 
range. Vertical bars indicate the epidemiological cut-off values used as breakpoints as defined by EUCAST. The dashed bars indicate 
the clinical breakpoints. 
Broilers
N = 291 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 0.7 6.5 16.2 3.4 0.3 72.9 73.2 68-78.4
Cefotaxime 63.2 17.2 1.7 0.7 0.3 1.0 15.8 17.9 13.7-22.3
Ceftazidime 79.4 3.1 3.4 6.5 0.7 1.7 3.1 2.1 17.5 13.4-22
Gentamicin 1.0 43.6 37.1 9.6 1.4 0.7 2.4 2.7 1.4 8.6 5.5-12
Kanamycin 63.2 19.6 5.2 12.0 17.2 13.1-21.6
Streptomycin 5.8 18.9 7.9 6.9 7.9 9.6 43.0 67.4 61.9-72.5
Tetracycline 1.4 16.5 18.9 1.4 0.3 0.3 5.2 56.0 61.9 56.4-67.4
Sulfamethoxazole 28.2 0.3 71.5 71.5 66.3-76.6
Trimethoprim 37.5 0.3 62.2 62.2 56.7-67.7
Ciprofloxacin 34.4 7.6 0.7 6.5 27.8 14.8 2.7 1.0 1.7 2.7 57.4 51.5-62.9
Nalidixic acid 41.9 0.3 0.3 0.7 7.6 49.1 57.4 51.5-62.9
Chloramphenicol 7.2 55.3 13.7 2.1 4.8 16.8 23.7 18.9-28.5
Florfenicol 5.8 69.1 21.0 3.4 0.7 4.1 2.1-6.5
Colistin 0.3 99.7 0 0-0.01
Slaughter pigs
N = 296 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 2.7 13.5 36.1 2.7 0.3 44.6 44.9 39.2-50.7
Cefotaxime 85.8 10.1 0.3 0.3 3.4 3.7 1.7-6.1
Ceftazidime 92.2 4.1 1.4 1.0 0.3 1.0 3.7 1.7-6.1
Gentamicin 3.0 47.6 37.8 8.4 3.0 3.0 1.4-5.1
Kanamycin 78.7 13.9 3.7 0.3 3.4 7.4 4.7-10.5
Streptomycin 7.4 18.9 11.1 6.8 10.5 13.2 32.1 62.5 57.1-67.9
Tetracycline 2.7 13.2 14.9 1.7 1.0 6.8 59.8 67.6 62.2-73
Sulfamethoxazole 38.2 61.8 61.8 56.4-67.2
Trimethoprim 45.6 0.7 53.7 53.7 48-59.5
Ciprofloxacin 73.0 19.3 0.7 1.4 4.1 1.4 0.3 7.1 4.4-10.1
Nalidixic acid 92.6 0.3 1.0 6.1 7.1 4.4-10.1
Chloramphenicol 0.7 8.8 68.6 10.5 3.0 1.4 7.1 11.5 8.1-15.2
Florfenicol 10.5 70.9 17.9 0.7 0.7 0-1.7
Colistin 100.0 0 0-0.01
Veal calves
N = 171 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 0.6 12.3 43.3 2.3 41.5 41.5 33.9-49.1
Cefotaxime 81.3 13.5 3.5 1.8 1.8 0-4.1
Ceftazidime 94.2 3.5 1.2 0.6 0.6 2.3 0.6-4.7
Gentamicin 0.6 42.1 42.7 8.2 0.6 1.8 0.6 3.5 6.4 2.9-10.5
Kanamycin 70.2 11.1 2.3 0.6 15.8 18.7 12.9-24.6
Streptomycin 9.4 33.3 9.9 4.1 5.8 7.0 30.4 47.4 39.8-55
Tetracycline 0.6 11.1 27.5 1.8 4.1 55.0 59.1 51.5-66.1
Sulfamethoxazole 54.4 0.6 45.0 45.0 37.4-52.6
Trimethoprim 62.0 0.6 37.4 37.4 30.4-45
Ciprofloxacin 62.0 19.3 0.6 8.2 2.3 1.2 1.2 0.6 4.7 18.1 12.3-24
Nalidixic acid 80.1 1.2 0.6 2.3 15.8 18.7 12.9-24.6
Chloramphenicol 4.7 52.6 20.5 1.2 21.1 22.2 16.4-28.7
Florfenicol 4.1 64.3 24.6 0.6 6.4 7.0 3.5-11.1
Colistin 100.0 0 0-0.02
Dairy cattle
N = 136 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 2.2 23.5 58.8 3.7 11.8 11.8 6.6-17.6
Cefotaxime 75.0 22.8 0.7 1.5 1.5 0-3.7
Ceftazidime 96.3 2.2 1.5 1.5 0-3.7
Gentamicin 2.9 53.7 30.9 6.6 1.5 2.2 0.7 1.5 5.9 2.2-10.3
Kanamycin 79.4 11.8 3.7 0.7 4.4 8.8 4.4-14
Streptomycin 20.6 51.5 11.0 2.2 2.9 2.2 9.6 16.9 11-23.5
Tetracycline 2.2 33.8 43.4 2.2 0.7 1.5 16.2 18.4 11.8-25
Sulfamethoxazole 83.8 16.2 16.2 10.3-22.8
Trimethoprim 85.3 2.2 12.5 12.5 7.4-18.4
Ciprofloxacin 68.7 26.9 0.7 3.0 0.7 4.5 1.5-8.2
Nalidixic acid 92.6 0.7 0.7 0.7 5.1 5.9 2.2-10.3
Chloramphenicol 2.9 73.5 17.6 1.5 2.2 2.2 5.9 2.2-10.3
Florfenicol 2.9 78.7 16.2 0.7 1.5 2.2 0-5.1
Colistin 100.0 0 0-0.03
MIC (%) distribution mg/L
R% 95% CI
MIC (%) distribution mg/L
R% 95% CI
MIC (%) distribution mg/L
R% 95% CI
MIC (%) distribution mg/L
R% 95% CI
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Figure 7.1. Trends in resistance (in%) of E. coli isolated from 
broilers, slaughter pigs, veal calves, and dairy cattle in the 
Netherlands from 1998 – 2009. 
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Pigs 
Compared to 2008, E. coli isolated from slaughter pigs 
showed an increase in resistance for most antibiotics. 
Especially with regard to beta-lactam antibiotics 
(ampicillin, cefotaxime and ceftazidime), 
fluoroquinolones (nalidixic acid and ciprofloxacin), 
trimethoprim and sulfamethoxazole. This is an on-
going trend since approximately the turn of the 
century as shown in Figure 7.1. For instance 
ampicillin resistance raised from 16.6% in 1998 to 
44.9% in 2009. The observed 3.7% of the isolates 
being resistant against cefotaxime and ceftazidime 
resistance could indicate that similar to what was 
observed in broilers, also in pigs the prevalence of 
ESBL-producers is increasing.  
With regard to tetracycline, in 1998 resistance was 
detected in 48.0% of the E. coli strains, increasing to 
67.6% in 2009. Also for trimethoprim and 
sulfamethoxazole a significant increase in resistance is 
seen, from 32.8% (1998) to 53.7% and 52.7 (2004) to 
61.8% respectively.  
Resistance is variable for the aminoglycoside class 
antibiotics. Streptomycin resistance is common 
(62.5% in 2009), while 3.0% of the E. coli strains 
were resistant against gentamicin and 7.4% against 
kanamycin.  
Resistance against chloramphenicol and florfenicol 
has remained stable over the years, with an average 
rate around 10% for chloramphenicol and below 1% 
for florfenicol. 
 
Veal calves 
Over the last five years, resistance rates in E. coli 
isolated from veal calves seem to be relatively 
constant or  show a slight tendency to decrease. For 
beta-lactam antibiotics, resistance against ampicillin is 
commonly seen (41.5% in 2009). However, resistance 
against 3rd generation of cephalosporins like 
cefotaxime and ceftazidime remains relatively low 
(1.8 and 2.3% respectively). 
Remarkably, resistance against tetracyclines has 
decreased from 2005 onwards. In 2005 as much as 
82.4% of all E. coli form veal calves tested were 
resistant against tetracycline, compared to 59.1% in 
2009. 
With regard to fluoroquinolone resistance, about 
18.1% of E. coli from veal calves showed reduced 
susceptibility to ciprofloxacin, 6.5% were considered 
clinically resistant with MIC values >1 mg/L. The 
percentage of E. coli with acquired resistance 
mechanisms against ciprofloxacin in 2009 was higher 
among veal calves compared to pigs (7.1%) and dairy 
cattle (4.5%), but lower than seen in broilers (57.4%). 
This likely reflects the use of quinolones in various 
animal husbandries. 
 
Dairy cattle 
In general, resistance in E. coli isolated from dairy 
cattle is low compared to resistance levels seen in 
pigs, broilers and veal calves. However, in dairy cattle 
a prominent increase in resistance has been observed 
over the last five years as shown in Figure 7.1. In 
2009, resistance was observed for all antibiotics tested 
except colistin. Highest resistance was observed for 
tetracycline (18.4% of E. coli isolated from dairy 
cows), followed by streptomycin (16.9%), and 
sulfamethoxazole (16.2%). A plausible explanation for 
this increase in resistance is currently lacking. 
 
Multidrug resistance 
The overall increase in resistance is also reflected in 
de multidrug resistance data as shown in Figure 7.2. In 
commensal E. coli from all animal host species, 
resistance was discovered against up to eight out of 
nine tested classes of antibiotics (represented by 
ampicillin, cefotaxime, gentamicin, tetracycline, 
sulfamethoxazole, trimethoprim, nalidixic acid, 
chloramphenicol, and kanamycin).  
The highest level of multidrug resistance was present 
among E. coli originating from broilers. Only 12% of 
the commensal E. coli strains from broiler chickens 
were fully susceptible to all antimicrobials tested. As 
much as 27.5% of the isolates showed resistance to six 
or more classes of antibiotics, 2.5% was resistant to 
eight classes. Also among E. coli from veal calves and 
pigs, multidrug resistance was widespread although 
less common compared to broilers. Amid E. coli from 
veal calves, 11.1% was resistant to six or more classes 
of antibiotics, for porcine E. coli this was the case for 
4.4% of the isolates. For E. coli from dairy cattle 
multidrug resistance is most favourable, although 
rapidly expanding. In 2005, less than 2% of the E. coli 
from dairy cattle was resistant to one or more 
antibiotics. In 2009, this increased more than tenfold 
with 2.9% of E. coli strains showing reduced 
susceptibility to eight antibiotic classes. 
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Figure 7.2. Trends in percentages of E. coli strains fully 
susceptible, resistant to one to a maximum of nine tested 
antimicrobial classes in broiler chickens, slaughter pigs and veal 
calves in the Netherlands from 1998 - 2009. 
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Table 7.2. Resistance (in %) of E. coli isolated from raw meat products at 
retail in the Netherlands in 2009. 
 
 
 
 
E. coli in raw meat products of food-animals 
Table 7.2 shows resistance percentages of E. coli 
strains isolated from raw meat products sampled at 
retail in the Netherlands by the Dutch Food and 
Consumer Product Safety Authority (VWA).  
Overall, resistance percentages of E. coli strains 
isolated from poultry products were similar to those 
isolated as indicator organisms from faecal samples of 
Dutch broiler chickens (Tables 7.1 and 7.2). As in 
previous years, resistance against sulfamethoxazole 
was higher in isolates from meat products than in 
isolates from live animals for all three animal species. 
This may reflect a difference in methodology between 
the different labs due to the complex nature of reading 
test results for sulfonamides.  
Interpretation of data from both pork and veal is 
complicated by the low number of isolates from meat 
products that are tested. This is reflected in the 
variability in resistance rates over the years as shown 
in Figure 7.3. Trends in resistance percentages from E. 
coli isolated from poultry meat show a tendency to 
increase, similar to resistance percentages from 
indicator bacteria isolated from faecal samples. 
Resistance rates of E. coli from beef samples are 
stable over the years.  
 
E. coli in other European countries10 
Although not from all European countries data are 
available, in E. coli from food producing animals and 
raw meat, the resistance percentages are among the 
highest reported in Europe. Of particular concern is 
the level of resistance to 3rd generation cephalosporins 
                                                     
10 The Community Summary Report. Antimicrobial resistance 
in zoonotic and indicator bacteria from humans, animals and 
food in the European Union in 2009. 
in poultry and poultry meat, for which only Spain 
reports a higher level of resistance and most other 
countries report levels between 0 and 3%. 
 
Poultry meat Pork Beef
N = 328 N = 13 N = 79
Ampicillin 67.7 30.8 15.2
Cefotaxime 21.3 7.7 1.3
Ceftazidime 18.0 7.7 1.3
Gentamicin 10.4 0.0 2.5
Kanamycin 19.5 15.4 8.9
Streptomycin 55.5 53.8 17.7
Tetracycline 60.1 69.2 17.7
Sulfamethoxazole 90.9 92.3 96.2
Trimethoprim 53.0 46.2 8.9
Ciprofloxacin 49.7 0.0 3.8
Naladixic acid 48.8 0 3.8
Chloramphenicol 22.3 23.1 8.9
Florfenicol 2.4 0 3.8
Colistin 2.1 0.0 0.0
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Figure 7.3. Trends in resistance (in%) of E. coli isolated from raw poultry meat 
products, beef, and pork, in the Netherlands from 2002 – 2009.  
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Enterococcus faecalis and Enterococcus faecium 
 
This chapter presents information on resistance in 
Enterococcus species from food-producing animals in 
the Netherlands as indicator organisms for the 
occurrence and trends in resistance in Gram-positive 
bacteria. Enterococcus faecalis and Enterococcus 
faecium isolates were selected from fecal samples of 
chickens, pigs, and cattle. Supplementary to isolates 
from live animals, susceptibility profiles of E. faecalis 
and E. faecium isolated from raw meat are presented.  
In 2009 MIC values have been determined for 194 E. 
faecalis and 298 E. faecium strains isolated from fecal 
samples of animals at abattoirs as well as for 238 E. 
faecalis and 74 E. faecium isolates from different 
meat samples. In Table 7.3 MIC distributions are 
summarized for all E. faecalis and E. faecium strains 
isolated from live animals. Table 7.4 presents 
information on resistance rates in different animal 
species, specified for broiler chickens, slaughter pigs, 
veal calves and dairy cows. Trends over the years are 
depicted in Figure 7.4.  
Data for 2009 on E. faecalis and E. faecium from 
different meats are presented in Table 7.5. as well as 
in Figure 7.5 (trends in resistance percentages for E. 
faecalis and E. faecium from 2003 to 2009). 
 
 
Highlights 
 
Overall, enterococci displayed high levels of resistance against tetracycline (92.8% for E. faecalis, 71.1% for E. 
faecium) and erythromycin (69.6% for E. faecalis, 56.7% for E. faecium). Also resistance against streptomycin was 
common in 2009 (51.0% for E. faecalis, 41.9% for E. faecium). Notable was the increase in resistance against 
ampicillin among E. faecium isolates from pigs, broilers and veal calves. 
Resistance was generally higher in E. faecium isolates than in E. faecalis isolates, while resistance to tetracycline, 
erythromycin, streptomycin and chloramphenicol was lower. 
Vancomycin resistance was observed in low levels in E. faecium (1.0%). 
 
 
 
 
Highest resistance levels among the Enterococcus 
species were detected for tetracyclines, against which 
92.8% of all E. faecalis and 71.1% of E. faecium 
isolates were resistant (Table 7.3.). In E. faecalis 
resistance rates were generally high in all host animal 
species. However, among E. faecium isolates levels 
varied for different animal species as shown in Table 
7.4. Highest level of tetracycline resistance (90.7%) 
was present in E. faecium from slaughter pigs, 
compared to only 25.0% of E. faecium isolated from 
dairy cows. Levels in E. faecium from broiler 
chickens and veal calves were 76.3% and 60.5% 
respectively. It is noticeable that in all animal species 
resistance levels in both enterococcus species show a 
tendency to increase from 2006/2007 onwards (Figure 
7.4). Most striking is the rise in tetracycline resistance 
in E. faecalis isolated from dairy cows (from 23.1% in 
2005 to 84.2% in 2009). An exception is tetracycline 
resistance in E. faecium from veal calves, where levels 
have decreased from 96.2% in 1996/1997 to 60.5% in 
2009 (Figure 7.4). It should be noted however, that for 
some bacterial subspecies/host animal combinations a 
limited number of data is available, making 
interpretation more difficult. With respect to E. 
faecalis and E. faecium from raw meat, tetracycline 
resistance is also common, although more variable 
(Table 7.5 and Figure 7.5). Again this may be due to 
limited number of isolates. In general, resistance 
levels seem to be somewhat lower in enterococcal 
species recovered from raw meat compared those 
from live animals. 
As expected, ampicillin resistance was detected in E. 
faecium. However, in 2009 resistance levels show a 
marked increase in strains isolated from pigs (45.4%), 
broiler chickens (40.4%)as well as in veal calves 
(30.2%) as illustrated in Figure 7.4. Also for E. 
faecium recovered from pork a higher percentage of 
resistant strains is found in 2009 compared to previous 
years (Figure 7.5). These findings are in line with the 
increased resistance seen in E. coli. 
 
Resistance against erythromycin in 2009 was 
commonly seen in both E. faecalis (69.6%) and E. 
faecium (56.7%) as summarized in Table 7.3. Over a 
longer period of time, erythromycin resistance rates 
are somewhat variable, although  different trends are 
detectable in distinct animal host species (Figure 7.4), 
probably reflecting usage patterns. Macrolides in 
poultry, calves and pigs are predominantly used as 
flock or group treatment versus administration in 
dairy cows by injection only. 
In 2009, resistance against erythromycin is highest in 
broiler chickens (81.8% for E. faecalis and 79.8% for 
E. faecium). Historically, erythromycin resistance 
rates for E. faecalis and E. faecium were much higher 
in veal calves compared to dairy cattle. In 2009, this is 
still true for E. faecium. However a decrease in 
erythromycin resistance in E. faecalis strains from 
veal cattle combined with an increase in resistance in 
E. faecalis from dairy cows resulted in similar levels 
in both categories in 2009 (Figure 7.4). 
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Table 7.3. MIC distributions (in %) for Enterococcus faecalis (N=194) and Enterococcus faecium (N=298) 
isolated in food animals in the Netherlands in 2009. 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the highest 
concentration in the range. Values at the lowest concentration tested indicate MIC-values  the lowest concentration in the range. Vertical 
bars indicate the epidemiological cut-off values used as breakpoints. The dashed bars indicate clinical breakpoints. 
 
 
 
In general, erythromycin resistance in E. faecalis and 
E. faecium isolated from fresh meat is lower 
compared to isolates recovered from fecal samples. 
However, trends over the years are similar in isolates 
from both sources. 
 
As in previous  years, vancomycine resistance is 
occasionally present among E. faecium strains isolated 
from animals. In 2009 two highly resistant strains 
were isolated, from a chicken and from a pig. Both 
strains were also resistant against tetracycline, 
erythromycin and quinupristin-dalfopristin. The 
galline strain showed additional resistance against 
streptomycin and salinomycine, the porcine strain 
against ampicillin.  
 
In 2009 again high level ciprofloxacin resistant E. 
faecalis and E. faecium isolates were observed (MIC 
≥16 mg/l) as shown in Table 7.3. Acquired 
ciprofloxacin resistance shows some variation among 
the animal species, and appears to slightly increase 
over the years as shown in Figure 7.4. Overall, 
resistance levels are somewhat higher in E. faecium 
compared to E. faecalis. 
 
Also resistance against salinomycine is more often 
encountered in E. faecium than in E. faecalis (37.2% 
and 5.7% respectively) as well as for the 
streptogramin combination of quinupristin and 
dalfopristin (synercid®) (80.5% versus 0%). This 
combination is a last resort drug for the treatment of 
infections caused by staphylococci and vancomycine-
resistant E. faecium (VRE). Although acquired 
resistance was observed in a high percentage of E. 
faecium it should be noted that the majority of 
reduced susceptible strains show MIC values below 
the clinical breakpoint value of >4 mg/ml. With 
respect to E. faecium strains recovered from meat 
samples, resistance rates have increased over the years 
to similar rates as seen in E. faecium isolated from 
live animals. 
0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 4096
Ampicillin 85.6 12.4 1.0 1.0 1.0 0-2.6
Linezolid 21.1 78.4 0.5 0 0-0.02
Tetracyline 4.6 2.6 1.0 28.9 22.7 40.2 92.8 89.2-96.4
Erythromycin 7.2 9.8 13.4 0.5 1.0 3.1 2.1 0.5 62.4 69.6 62.9-75.8
Vancomycin 0.5 41.2 41.2 17.0 0 0-0.02
Ciprofloxacin 9.3 83.0 4.1 2.6 1.0 1.0 0-2.6
Quinu/dalfopristin 0.5 1.5 1.0 39.7 52.6 4.6 0 0-0.02
Salinomycin 10.8 46.9 5.2 31.4 5.7 5.7 2.1-8.2
Streptomycin 3.1 36.1 9.3 0.5 1.5 49.5 51.0 43.8-58.2
Gentamicin 1.0 18.0 74.7 4.1 0.5 1.5 2.1 0.5-4.1
Chloramphenicol 0.5 76.8 3.6 1.0 6.2 11.9 18.0 12.9-23.7
Florfenicol 4.6 95.4 0 0-0.02
0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 4096
Ampicillin 22.8 23.5 18.8 28.5 1.3 5.0 34.9 29.4-40.1
Linezolid 2.0 68.1 29.5 0.3 0.3 0-1.0
Tetracyline 28.2 0.7 0.3 2.0 16.8 52.0 71.1 65.9-76.3
Erythromycin 15.8 17.1 10.4 2.3 0.3 0.3 0.3 53.4 56.7 50.8-62.2
Vancomycin 51.3 35.9 8.7 3.0 0.3 0.3 0.3 1.0 0-2.3
Ciprofloxacin 5.7 24.2 21.5 35.2 12.1 1.0 0.3 13.4 9.7-17.4
Quinu/dalfopristin 8.7 10.7 16.8 52.7 9.4 1.0 0.7 80.5 75.6-84.6
Salinomycin 0.3 32.6 25.2 4.7 37.2 37.2 31.8-42.5
Streptomycin 0.3 0.7 38.9 18.1 0.3 0.7 2.3 38.6 41.9 36.1-47.5
Gentamicin 9.7 37.6 39.9 6.7 1.3 2.3 2.3 6.0 3.3-8.7
Chloramphenicol 1.7 66.4 17.8 12.4 1.7 1.7 0.3-3.3
Florfenicol 1.3 91.9 6.4 0.3 0.3 0-1.0
95% CI
95% CI
E. faecalis 
(n=194)
MIC (%) distribution mg/L
R%
E. faecium 
(n=298)
MIC (%) distribution mg/L
R%
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Table 7.4. Resistance percentages (%) of Enterococcus faecalis and Enterococcus faecium 
isolated from faeces from slaughter pigs, broilers, veal calves, and dairy cows in the 
Netherlands in 2009. 
           
 
 
 
Resistance against streptomycin is rather common in 
E. faecalis and E. faecium, roughly up to 50% of the 
isolates are resistant, with some variation over the 
different animal host species. Typically, streptomycin 
resistant Enterococcus strains display high MIC 
values of >1024 mg/ml. 
Gentamicin resistance is occasionally found in both E. 
faecalis and E. faecium. Generally, highest levels of 
resistance against aminoglycoside antibiotics are 
found in E. faecium isolates from broiler (61.4% 
streptomycin resistant and 13.2% gentamicin 
resistant). Compared to E. faecalis and E. faecium 
from fecal samples, isolates from meat samples 
usually show lower levels of resistance against 
aminoglycosides. 
 
Typically E. faecium strains are susceptible to 
chloramphenicol and florfenicol, while among E. 
faecalis chloramphenicol resistance is more 
commonly detected. In 2009, highest levels were seen 
in strains isolated from fecal samples from pigs 
(41.9%), and also regularly detected in bovine 
samples (22.7% from veal calves and 26.3% from 
dairy cows). Compared to live animals, levels of 
chloramphenicol resistance in Enterococcus species 
from meat samples were lower as summarized in 
Table 7.5. 
 
E. faecalis 
Slaughter pigs    
(43)
Broiler chickens 
(110)
Veal calves        
(22)
Dairy cows        
(19)
Ampicillin 0 1.8 0 0
Linezolid 0 0 0 0
Tetracyline 93.0 95.5 86.4 84.2
Erythromycin 65.1 81.8 40.9 42.1
Vancomycin 0 0 0 0
Ciprofloxacin 2.3 0 4.5 0
Salinomycin 4.7 7.3 0 5.3
Quinu/dalfopristin 0 0 0 0
Gentamicin 2.3 0.9 4.5 5.3
Streptomycin 51.2 56.4 40.9 31.6
Chloramphenicol 41.9 6.4 22.7 26.3
Florfenicol 0 0 0 0
E. faecium
Slaughter pigs    
(97)
Broiler chickens 
(114)
Veal calves        
(43)
Dairy cows        
(44)
Ampicillin 45.4 40.4 30.2 2.3
Linezolid 0 0 2.3 0
Tetracyline 90.7 76.3 60.5 25.0
Erythromycin 50.5 79.8 48.8 18.2
Vancomycin 1.0 0.9 0 2.3
Ciprofloxacin 6.2 17.5 16.3 15.9
Salinomycin 23.7 71.1 14.0 2.3
Quinu/dalfopristin 94.8 81.6 67.4 59.1
Gentamicin 1.0 13.2 4.7 0
Streptomycin 34.0 61.4 39.5 11.4
Chloramphenicol 2.1 0.9 2.3 2.3
Florfenicol 0 0 2.3 0
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Figure 7.4. Trends in resistance percentages of Enterococcus faecium and Enterococcus faecalis isolated from 
slaughter pigs, broilers and veal calves in the Netherlands from 1996 – 2009. 
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Enterococcus faecalis and Enterococcus faecium in raw meat products of food-animals 
 
Table 7.5. Resistance % of Enterococcus faecalis and Enterococcus faecium strains isolated from 
raw meat products from pork, poultry, beef, veal, and lamb in the Netherlands in 2009. 
       
 
 
 
Enterococci in other European countries11 
In 2009, information on antimicrobial resistance in 
enterococci from animals and food from eight 
European countries showed a wide variation in the 
levels of resistance. To the same extend as in E. coli, 
the resistance percentages in Enterococci from food 
producing animals in the Netherlands are among the 
highest reported in Europe.  
Especially the high resistance levels observed to 
macrolides are considered of particular significance 
because these substances have been defined as 
critically important antimicrobial in human medicine. 
                                                     
11The Community Summary Report. Antimicrobial resistance in 
zoonotic and indicator bacteria from humans, animals and food 
in the European Union in 2009. 
E. faecalis 
Pork            
(21)
Poultry         
(172)
Beef            
(32)
Veal            
(7)
Lamb      
(6)
Ampicillin 0 0 0 0 0
Linezolid 0 0 0 0 0
Tetracyline 23.8 77.4 34.4 42.9 16.7
Erythromycin 4.8 69.0 0 14.3 0
Vancomycin 0 1.1 0 0 0
Ciprofloxacin 0 4.0 0 0 0
Salinomycin 0 8.5 0 0 0
Quinu/dalfopristin 0 1.1 0 0 0
Gentamicin 0 2.3 0 14.3 0
Streptomycin 4.8 47.5 12.5 28.6 0
Chloramphenicol 4.8 4.5 0 28.6 0
Florfenicol 0 0 0 0 0
E. faecium
Pork            
(5)
Poultry         
(43)
Beef            
(22)
Veal            
(3)
Lamb      
(2)
Ampicillin 20.0 4.7 0 0 0
Linezolid 0 0 0 0 0
Tetracyline 40.0 40.9 0 33.3 0
Erythromycin 20.0 39.5 9.1 33.3 50.0
Vancomycin 0 0 0 0 0
Ciprofloxacin 0 13.6 0 0 0
Salinomycin 0 43.2 0 0 0
Quinu/dalfopristin 80.0 90.9 68.2 100.0 100
Gentamicin 0 3.4 0 0 0
Streptomycin 20.0 31.0 4.5 33.3 0
Chloramphenicol 0 0 0 0 0
Florfenicol 0 0 0 0 0
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Figure 7.5. Trends in resistance percentages in Enterococcus faecalis and Enterococcus faecium isolated from 
raw meat products from pork, poultry, and beef in the Netherlands from 2003 to 2009. 
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III  Appendices 
 
Appendix I. Prevalence of ESBL and/or AmpC producing E. coli in the Dutch broiler 
production chain 
 
C.M. Dierikx and D.J. Mevius, 
 
Introduction 
Since 2003, a dramatic increase in occurrence of 
cefotaxime-resistant Escherichia coli and Salmonella 
enterica isolates from Dutch broiler chickens was 
observed. In 2008, 15% of E. coli randomly isolated 
from faecal samples using non-selective plates was 
cefotaxime-resistant, compared to 3% in 2003 
(Anonymous, 2010). Genetic analysis of E. coli 
isolates from 2006 demonstrated that the cefotaxime-
resistant isolates all harbored a plasmid mediated 
ESBL (blaCTX-M-1, blaCTX-M-2, blaTEM-52, blaTEM-20, 
blaSHV-2) or an AmpC-type beta-lactamase (blaCMY-2) 
(Dierikx et al., 2010).  Information on the prevalence 
of these ESBL and/or AmpC-producing isolates on 
Dutch broiler farms was lacking. Therefore in a pilot 
study on 26 broilers production farms the prevalence 
of ESBL and/or AmpC producing E. coli was 
determined. From 25 to 41 animals per farm faecal 
samples were collected from the cloaca using sterile 
cotton swabs. All farms were found positive and on 
85% of the farms in up to 80% of examined broiler 
chickens ESBL and/or AmpC producing E. coli were 
detected (Dierikx, 2010). To understand more about 
the spread of ESBL and/or AmpC producing E. coli in 
the Dutch broiler industry, different levels in the 
broiler production chain were examined for the 
presence and prevalence of these bacteria. 
 
Methods used 
Between July 2009 and January 2011 the Dutch 
broiler production chain was investigated for the 
presence of cefotaxime-resistant E. coli. Faecal 
samples were taken from day-old chickens at 
hatcheries (parents and broiler chickens) or 
grandparent farms. All samples were inoculated 
overnight on MacConkey agar with 1 mg/L 
cefotaxime and in enrichment broth using Luria 
Bertani (LB) broth + 1 mg/L cefotaxime and 
incubated aerobically overnight at 37°C. If the 
following day no growth was observed on the agar 
plate, 10 µl of the enrichment broth was inoculated on 
MacConkey agar with 1 mg/L cefotaxime and 
incubated overnight at 37°C. From each plate one 
morphologically suspected colony was biochemically 
confirmed to be E. coli. All E. coli isolates were tested 
phenotypically for their susceptibility to cefotaxime, 
ceftazidime, both as single drugs and as combination 
disks with clavulanic acid, and cefoxitin according to 
CLSI M100-S20. Based on the phenotype the isolates 
were classified as Extended Spectrum Beta-Lactamase 
(ESBL) or AmpC-producers. As a rule, ESBL-
producers are resistant to cefotaxime and/or 
ceftazidime. One or both of these cephalosporins is 
synergistic with clavulanic acid and the isolates are 
susceptible to cefoxitin. AmpC-producers are resistant 
to cefotaxime and/or ceftazidime, but without synergy 
with clavulanic acid and are resistant to cefoxitin.  
 
Results 
Grandparent day-old chickens 
Two breeds of chickens were examined. From breed 
A, a total of 80 animals were sampled. The animals 
were derived from eight different production farms 
(located outside the Netherlands) and from each 
location 10 animals were screened by sampling caecal 
content (the animals were sacrificed by the producer 
for other screening tests). Animals from two 
production farms were negative. The overall 
prevalence of ESBL and/or AmpC-producing E. coli 
was 22.5% (Table A1). The prevalence ranged from 
0% to 70% per production farm. 
For breed B meconium was examined from a total of 
125 animals. The animals were derived from five 
different production farms (located outside the 
Netherlands), 25 animals per farm. The overall 
prevalence was 44%, ranging from 36% to 60%. 
 
Parent day-old chickens 
Two breeds of parent broiler chickens were examined. 
From breed A, meconium samples were taken in 
hatching units from 649 animals derived from nine 
different production farms. A minimum of 25 samples 
were taken per production farm. Animals from five 
farms were found negative for ESBL and/or AmpC-
producing E. coli. The overall prevalence was 0.9%, 
ranging from 0% to 4% per production farm. 
From breed B meconium of a total of 325 animals, 
derived from eight different production farms, was 
examined. From five farms all animals examined were 
negative for ESBL and/or AmpC-producing E. coli. 
The overall prevalence was 5.8%, ranging from 0% to 
13% per production farm. 
 
Day-old broiler chickens 
Meconium samples from 425 broiler chickens, 
derived from 12 different production farms were 
examined at two hatcheries. Although at both 
hatcheries animals of breed A and B were produced, 
only animals from breed A were present at the 
sampling day. Again a minimum of 25 samples per 
production farm were examined. Samples derived 
from animals from seven production farms were 
negative for ESBL and/or AmpC-producing E. coli. 
The overall prevalence was 3.3%, ranging from 0% to 
20%. 
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Table A1. Results ESBL and/or AmpC-prevalence of day-old animals in the Dutch broiler production chain. 
 
 
 
 
Discussion and conclusions 
In the Dutch poultry production chain ESBL and/or 
AmpC producing E. coli were present at every level 
that was examined. Prevalence seems lower in day-old 
parent chickens and day-old broiler chickens and 
higher in day-old grandparent chickens which are 
derived from outside the Netherlands (UK and USA). 
The low prevalence in day-old broiler chickens is 
surprising as previous research showed that these 
animals at 6 weeks of age are almost all positive for 
ESBL and/or AmpC-producing E. coli (Dierikx, 
2010).  
Grandparents at week 18 and week 31 of age were 
found positive at moderate level (data not shown) 
which indicates that especially on Dutch broiler 
production farms optimum circumstances are present 
to multiply ESBL and/or AmpC-producing bacteria. 
Preliminary data on genetic analysis of these isolates 
show that throughout the production chain blaCTX-M, 
blaTEM and blaCMY are the predominant beta-lactamase 
families present.  
The data from this study show that ESBL and/or 
AmpC producing E. coli are introduced in the Dutch 
poultry production chain through imported day-old 
grandparent chickens. Moreover the data indicate that 
the occurrence of these organisms in the different 
levels of the Dutch poultry production chain is the 
result of vertical transmission, local recirculation and 
selection. Further research is currently conducted to 
understand more about the driving forces that lead to a 
rapid spread of ESBL and/or AmpC producing E. 
coli’s in broilers at the broiler production farms. 
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Animals sampled Breed Total number of 
samples
Number of farms 
of  which animals 
originated
ESBL E. coli 
positive samples
Overall percentage 
ESBL E. coli 
positive
Day-old grandparents A 80 8 18 22.5%
B 125 5 55 44.0%
Day-old parents A 649 9 6 0.9%
B 325 8 19 5.8%
Day-old broiler chickens A 425 12 14 3.3%
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Appendix II. Materials and Methods 
 
 
Salmonella enterica 
A total of 21,456 isolates were tested for antimicrobial 
susceptibility between 1999-2008 (Table A2). Human 
isolates (N=11,742) concerned a selection from first 
isolates sent to the Dutch National Institute of Public 
Health (RIVM) by the regional public health 
laboratories. All strains were the first isolates 
recovered from patients with salmonellosis. The 
majority of the isolates from pigs (N=1512) and cattle, 
including calves, (N=749) were sent to the RIVM by 
the Animal Health Service from a diversity of 
surveillance programs and clinical Salmonella 
infections. Those from chickens (broilers, including 
poultry products, N=1558; layers, reproduction 
animals and eggs, N=899) concerned mainly 
nonclinical Salmonella infections derived from a 
diversity of monitoring programs on the farm, 
slaughterhouses and at retail. The majority of isolates 
from pigs in 2008 concerned those from the Dutch 
component of the EU-baseline study. Isolates from a 
diversity of other sources have been analysed as well 
(animal fodder and human food products; other 
animals from animal husbandry and pets, samples 
from the environment, etcetera.). 
 
 
 
Table A2. Number of Salmonella isolates tested for susceptibility from 1999 – 2008 in the Netherlands. 
 
 
 
 
Representativeness of percentages of resistance for 
humans or animals over all types 
In principal, if isolates are selected randomly from a 
source the percentage of resistant strains within a 
source can be computed straightforwardly. Standard 
statistical considerations would apply to indicate 
significant differences between years and between 
animal and human sources. Table A3 shows that quite 
substantial numbers are needed to indicate significant 
differences in resistance percentages less than 10%. 
However, resistance strongly depends on Salmonella 
type and many different types are involved; a cocktail 
of types that differ between sources and that may 
differ between years. Moreover, low numbers tested 
and incidentally missed, or selected types with rare 
antibiograms, may influence the resulting resistance 
percentages. Finally the source definition in itself may 
be biased, as the reason for sending-in isolates, 
especially from cattle and pigs, is often unknown. This 
explains many of the irregularities between years. 
 
E. coli, E. faecium, E. faecalis and Campylobacter 
spp. isolated from slaughter pigs and broilers 
E. coli and E. faecium, E. faecalis and Campylobacter 
spp. were isolated from faecal samples taken from 
healthy animals by the Food and Consumer Product 
Safety Authority as part of the national control 
programs. Samples were taken at slaughterhouses 
(pigs and poultry samples), or at farms (veal calves 
and dairy cattle). For isolation of the above mentioned 
organisms one faecal sample was taken for each 
epidemiological unit (farm, flock or group of animals), 
or the caeca collected (broilers). At the laboratory the 
samples were 1:10 (w/v) diluted directly in buffered 
peptone solution with 20% glycerol and stored at –
20°C. After arrival of the samples, isolation of E. coli, 
E. faecium, E. faecalis and Campylobacter spp. was 
performed without delay at CVI-Lelystad or the Food 
and Consumer Product Safety Authority in Zutphen.  
For E. coli MacConkey agar and for the enterococci 
Slanetz and Bartley agar was inoculated with cotton 
swabs (E. coli), or 50 µl of a serial dilution 
(enterococci). A colony with typical morphology was 
subcultured to obtain a pure culture and stored at –
80°C in buffered peptone water with 20% glycerol. E. 
coli was identified biochemically. The final 
identification of the enterococci was done with 
Polymerase Chain Reaction (PCR) as described by 
Dutka Malen in 199512.  
For isolation of Campylobacter CCDA-agar with 32 
µg/ml cefoperazone and 10 µg/ml amphotericin B to 
                                                     
12 Dutka-Malen, S., S. Evers, and P. Courvalin, Detection of 
glycopeptide resistance genotypes and identification to the 
species level of clinically relevant enterococci by PCR. J Clin 
Microbiol, 1995. 33(1): p. 24-7. 
 
Total 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Human 11742 647 349 1055 862 1338 1339 1176 1273 1089 1502 1112
Pig 1512 31 195 114 168 127 119 120 115 135 335 53
Cattle 749 18 28 56 33 23 106 90 159 87 76 73
Chicken (misc.) 1016 0 10 174 172 160 29 30 116 159 90 76
Broilers (faeces/meat) 1558 68 110 143 212 206 110 82 164 54 303 106
Layers/Repro/Eggs 899 93 86 62 56 88 91 232 75 44 37 35
Other sources 3980 0 9 309 330 446 473 603 535 451 378 446
Total 21456 857 787 1913 1833 2388 2267 2333 2437 2019 2721 1901
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inhibit growth of Gram-negative bacteria and fungi, 
was directly inoculated with a cotton swab. All 
campylobacters were typed with PCR to the species 
level. Only C. jejuni and C. coli were tested for their 
susceptibility. All other spp. were excluded from the 
program. 
 
 
Table A3. Power analysis to show the sample sizes 
needed to indicate significant differences in 
resistance percentages between groups (for 
example between years or between human and 
animal sources). 
 
 
 
 
E. coli, E. faecium and E. faecalis isolated from raw 
meat products of food-animals 
For isolation of all bacterial species raw meat products 
were rinsed with Buffered Peptone Water (BPW). For 
E. coli 10 ml BPW rinse was enriched in 90 
MacConkey-, or Laurylsulphate broth. After overnight 
aerobic incubation at 44°C the broth was subcultured 
on Coli-ID agar (24 h at 44°C). For enterococci 10 ml 
BPW rinse was enriched in 90 ml Azide Dextrose 
broth. After overnight aerobic incubation at 44°C, the 
broth was subcultured on Slanetz and Bartley agar for 
48 hrs at 44°C. Identification was done biochemically. 
 
Shiga toxin producing E. coli O157 (STEC) 
For STEC both human and animal strains were 
included. All sorbitol negative human strains from all 
medical microbiological laboratories in the 
Netherlands were sent to RIVM for serovar O157 
confirmation and further typing. The animal strains 
were partly isolated in the monitoring programme of 
farm-animals of VWA/RIVM. These samples were 
taken at farms from faeces of healthy animals. One 
isolate per farm was included. Isolates from non-
human sources included strains isolated from samples 
taken in an attempt to trace a human infection. 
 
Susceptibility tests 
Susceptibility was tested quantitatively with the broth 
micro dilution test with cation-adjusted Mueller 
Hinton broth according to ISO standard 20776-1-2006 
or CLSI guidelines M31-A3 for Campylobacter spp.. 
For broth microdilution, microtitre trays were used 
with dehydrated dilution ranges of custom made 
panels of antibiotics. Trek Diagnostic Systems, in the 
UK, manufactured these microtitre trays. ATCC 
strains E. coli 25922 and E. faecalis 29212 were used 
daily to monitor the quality of the results. For quality 
control of the results of campylobacters, C. jejuni 
ATCC 33560 was used as control strain.  
The MICs were defined as the lowest concentration 
without visible growth. Strains with MICs higher than 
the epidemiological cut-off values and MIC-
breakpoints were considered non-wild type or 
resistant, respectively. Percentages of resistance were 
calculated. For Salmonella, the indicator organisms E. 
coli and enterococci and Campylobacter spp. 
EUCAST epidemiological cut-off values were used as 
prescribed by EFSA1314 (Table A4). For the animal 
pathogens clinical breakpoints were used (CLSI M31-
A3, M100-S19) as listed in Table A5. 
 
Data interpretation needs to take into account that for 
some antibiotics the epidemiological cut-off values are 
substantially lower than the previously used clinical 
breakpoints, which may have affected the level of the 
resistance percentages. These percentages indicate the 
acquisition of resistance in intrinsically susceptible 
bacteria population as an effect of determinants like 
antibiotic usage. They cannot directly be translated in 
therapeutic failure, when antibiotics would be used to 
treat infection with those organisms. 
                                                     
13Report from the Task Force of Zoonoses Data Collection 
including a proposal for a harmonized monitoring scheme of 
antimicrobial resistance in Salmonella in fowl (Gallus gallus), 
turkeys, and pigs and Campylobacter jejuni and C. coli in 
broilers, the EFSA Journal (2007), 96,1-46.  
 
14 Report from the Task Force on Zoonoses Data Collection 
including guidance for harmonized monitoring and 
reporting of antimicrobial resistance in commensal Escherichia 
coli and Enterococcus spp. from food animals 1. The EFSA 
Journal (2008) 141: 1-44 
 
R-group 1 R-group 2 Difference N1=N2
40% 30% 10% 287
30% 20% 10% 251
20% 10% 10% 211
70% 50% 20% 111
60% 40% 20% 95
50% 30% 20% 84
40% 20% 20% 70
30% 10% 20% 59
60% 30% 30% 23
Level of significance = 0,05 and Power = 0,7
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Table A4. Epidemiological cut-off values (mg/L) used for the classification of Salmonella, E. coli (indicator 
organism), Campylobacter spp. and enterococci. Isolates with MIC-values higher than those presented in this 
table are considered resistant.  
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Ampicillin 4 8 8 16 4 4
Cefotaxime 0.5 0.25 - - - -
Ceftazidime 2 0.5 - - - -
Chloramphenicol 16 16 16 16 32 32
Ciprofloxacin 0.06 0.06 1 1 4 4
Clarithromycin - - 8 32 - -
Colistin 8 8 - - - -
Erythromycin - - 4 16 4 4
Flavomycin - - - - - 16
Florfenicol 16 16 - - 8 8
Gentamicin 2 2 1 2 32 32
Kanamycin 8 8 - - - -
Linezolid - - - - 4 4
Nalidixic acid 16 16 16 32 - -
Neomycin - - 1 2 - -
Quinupristin-dalfopristin - - - - 1 32
Salinomycin - - - - 4 4
Streptomycin 32a 16 2 4 128 512
Sulfamethoxazole 256b 256b 256 256 - -
Tetracycline 8 8 2 2 2 2
Trimethoprim 2 2 - - - -
Tulathromycin - - 16 16 - -
Vancomycin - - - - 4 4
a recommended by EFSA
b CLSI breakpoint
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